[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:carcinoma":31},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,36,0,25,[9,49,62,85,127,165,196,223,258,284,313,339,365,399,424,461,482,503,523,597,619,676,701,722,758],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100053608","phase-2-multitargeted-recombinant-ad5-psamuc-1brachyury-based-immunotherapy-triadeno-vaccine-with-il-15-superagonist-n-803-in-participants-with-clinically-localized-prostate-cancer-undergoing-active-surveillance-100053608",false,"NCT07574541","Multitargeted Recombinant Ad5 PSA\u002FMUC-1\u002FBrachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance","Phase II Trial of a Multitargeted Recombinant Ad5 PSA\u002FMUC-1\u002FBrachyury-based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance","* INCLUSION CRITERIA:\n* Histologically confirmed diagnosis of organ confined, low- or intermediate-risk PCa (Gleason grade group 1 or 2) identified in at least one prostate biopsy core. Biopsies performed at outside institutions should have Gleason score confirmed at the NCI by a genitourinary (GU) pathologist.\n* Participants must be on active surveillance.\n* Pre-study treatment tissue availability (at least one formalin-fixed paraffin embedded \\[FFPE\\] biopsy core or one H and E-stained slide and at least 5 unstained slides) obtained between 3 and 24 months prior to treatment initiation is mandatory for study initiation.\n* Serum PSA level of \\\u003C20 ng\u002FmL (or \\\u003C10ng\u002FmL for participants being treated with 5- alpha-reductase inhibitors)\n* Clinical stage \\\u003C=T2a by digital rectal exam (DRE)\n* Age \\>=18 years\n* Eastern Cooperative Oncology Group (ECOG) performance status \\\u003C=1.\n* Adequate organ and marrow function as defined below:\n\n  * Absolute neutrophil count (ANC) \\>=1.0 x 109\u002FL\n  * Hemoglobin (Hgb) \\>=9 g\u002FdL\n  * Platelets \\>=75,000\u002FmcL\n  * Prothrombin International Normalized Ratio (INR) \\\u003C1.5 x upper limit of normal (ULN)\n  * Partial thromboplastin time (PTT) \\\u003C1.5 x ULN\n  * Total bilirubin \\\u003C1.5 x ULN\n  * Aspartate aminotransferase (AST) \\\u003C=2.5 x ULN\n  * Alanine aminotransferase (ALT) \\\u003C=2.5 x ULN\n  * Creatinine \\\u003C=1.5 x ULN\n\nOR\n\n--Calculated Creatinine clearance \\>=40 mL\u002Fmin\u002F1.73 m2 for individuals with creatinine levels above institutional normal (using either Chronic Kidney Disease Epidemiology Collaboration \\[CKD-EPI\\] equation)\n\n* Treatment with steroid therapy must have a washout of at least 6 weeks prior to initiation of study treatment. Physiologic (replacement) doses of steroids as well as nasal, topical, or inhaled steroids are allowed.\n* Vaccination with a live (attenuated) vaccine (e.g., FluMist(R)) or a killed (inactivated)\u002Fsubunit vaccine (e.g., PNEUMOVAX(R), Fluzone(R)) must occur not sooner than 28 days or 14 days, respectively, prior to initiation of study treatment.\n* Participants must agree to use an effective method of contraception (barrier, surgical sterilization, abstinence) for the duration of the study treatment and up to one (1) month after the last vaccine injection. We also will recommend participants with female partners of childbearing potential to ask them to be on highly effective birth control (hormonal, intrauterine device \\[IUD\\], surgical sterilization). Participants must not freeze or donate sperm within the same period.\n* Participants must be able to understand and willing to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n* Prior treatment for PCa by surgery, radiation, local ablative (i.e., cryosurgery or highintensity focused ultrasound), or androgen-deprivation therapy.\n* Evidence of PCa with metastatic disease.\n* Prior treatment with adenovirus-based vector immunotherapy, adenovirus-based vaccines, or investigational vaccines.\n* Prior solid organ or bone marrow transplant.\n* Immunodeficiency or splenectomy.\n* Presence of a known active acute or chronic infection, including human immunodeficiency virus (HIV), confirmed by PCR, and hepatitis B virus (HBV) and hepatitis C virus (HCV), as determined by hepatitis B surface antigen (HBsAg) and HCV serology.\n* History of autoimmune disease (active or past), except for autoimmune-related thyroid disease, type I diabetes, and vitiligo if the condition(s) is well controlled.\n* History of heart disease, such as congestive heart failure (class II, III, or IV defined by the New York Heart Association functional classification), history of unstable or poorly\n\ncontrolled angina, or history (\\\u003C1 year prior to initiation of study therapy) of ventricular arrhythmia.\n\n* Acute or chronic skin disorders that will interfere with injection into the skin of the extremities or subsequent assessment of potential skin reactions.\n* Second malignancy within 3 years prior to initiation of study therapy. Note: Individuals with curatively treated non-melanoma skin cancers or non-muscle invasive bladder cancer will not be excluded.\n* History of herbal products that may decrease PSA levels (e.g., saw palmetto).\n* Participants who have undergone surgery within 4 weeks prior to initiation of study therapy.\n* Participants receiving any other investigational agents within 30 days prior to initiation of study therapy.\n* History of allergic reaction attributed to compounds of similar chemical or biological composition to the study drugs.\n* Uncontrolled intercurrent illness that would limit compliance with study requirements suggested by medical history, physical examination, or standard clinical assessments such as imaging, EKG, and laboratory studies.","MALE","18 Years","120 Years",{"count":21,"type":22},52,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","Background:\n\nProstate cancer is the second most common cause of cancer-related death among men in the United States. Early-stage, low-grade prostate cancer is managed with active monitoring. However, 35% of men with this cancer will need treatment within 5 years because of tumor growth. Researchers want to know if a new vaccine that targets 3 anti-cancer proteins (TriAdeno) plus a drug (N-803) approved for bladder cancer can help stop prostate tumors from growing.\n\nObjective:\n\nTo test TriAdeno and N-803 in people with early-stage prostate cancer.\n\nEligibility:\n\nPeople aged 18 years and older with early-stage low- or medium-risk prostate cancer.\n\nDesign:\n\nParticipants will be screened. They will have a physical exam with blood tests. They will have a test of their heart function. They will have an imaging scan. They may have a rectal exam.\n\nTriAdeno is injected under the skin of the upper thigh; N-803 is injected under the skin of the abdomen. Participants will be treated in up to four 21-day cycles. They will get both injections on the first day of each cycle.\n\nParticipants may opt to complete a memory aid: They may record all of their symptoms for 7 days after each injection. They may also complete a questionnaire about their prostate symptoms.\n\nBlood tests, imaging scans, and other tests will be repeated during the study.\n\nA tissue sample (biopsy) of the tumor will be collected during or after cycle 2; a second biopsy may be taken about 1 year later.\n\nParticipants will have follow-up phone calls for 5 years....",[28,29,30,31,32,33],"Adenocarcinoma","Prostate Cancer","Neoplasms","Carcinoma","Neoplasms, Glandular and Epithelial","Neoplasms by Histologic Type",[35],"Immune Infiltration","NOT_YET_RECRUITING","2026-07-10",{"date":39,"type":40},"2026-07-13","ACTUAL",{"date":42,"type":22},"2026-07-16",{"date":44,"type":22},"2028-06-15",{"name":46,"class":47},"National Cancer Institute (NCI)","NIH",1,{"id":50,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":26,"conditions":53,"keywords":54,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":61,"locationsCount":48},"100641793",{"count":21,"type":22},[25],[28,29,30,31,32,33],[35],"2026-07-01",{"date":57,"type":40},"2026-07-02",{"date":59,"type":22},"2026-07-07",{"date":44,"type":22},{"name":46,"class":47},{"id":63,"slug":64,"hasResults":12,"nctId":65,"briefTitle":66,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":12,"sex":69,"minAge":18,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":4},"100564522","canadian-initiative-to-measure-predict-and-assess-cancer-treatment-outcomes-in-patients-treated-with-immuno-oncotherapeutics-100564522","NCT06630273","Canadian Initiative to Measure, Predict and Assess Cancer Treatment Outcomes in Patients Treated With Immuno-Oncotherapeutics","(CAN-IMPACT-IO","Inclusion Criteria:\n\n* Willingness to submit a blood sample for buffy-coat and at least one tumour biospecimen.\n* CAN-PREDICT-IO subgroup:\n\nProvision of pre-treatment fresh tumour biopsy\u002Fresection tumour tissue for patients who will receive IO treatment, in a specified list of IO therapeutic trials currently active in CCTG.\n\nOR\n\n* CAN-PIVOT subgroup:\n\nProvision of on-treatment or at-progression fresh tumour biopsy\u002Fresection tumour tissue for patients who have received IO treatment, in a specified list of IO therapeutic trials currently active in CCTG.\n\nThere are 2 CAN-PIVOT subgroups: Primary resistance is defined as disease progression evident in initial on-treatment imaging or disease stability lasting less than six months. Acquired resistance, on the other hand, manifests as disease progression subsequent to an initial partial or complete response or after a period of disease stability lasting six months or more. Patients on adjuvant treatment, with no evidence of disease (NED) by radiological assessment who develop disease (local recurrence or metastases) after or while on immunotherapy are included.\n\n* Archived formalin fixed paraffin embedded (FFPE) blocks or slides would only be collected from patients who met CAN-IMPACT-IO study criteria and underwent fresh tumour biopsy\u002Fresection following consent but had a tumour specimen deemed insufficient for WGTS. The FFPE sample may be used to provide an alternate source of tumour tissue for WGTS in such cases. Where local centre regulations prohibit submission of blocks of tumour tissue, a predetermined number of unstained slides of representative tumour tissue may substitute the tumour block.\n* Participant consent for the CAN-IMPACT-IO study must be appropriately obtained in accordance with applicable local and regulatory requirements.","ALL",{"count":71,"type":22},120,"OBSERVATIONAL","The researchers doing this study are interested in doing the following:\n\n* Biomarker research using fresh tumour tissue and normal blood cells, and if required, tumour tissue already collected.\n* Bio-banking for use in future research using the collected tumour tissue \u002F blood .",[31],"2026-06-29",{"date":77,"type":40},"2026-06-30",{"date":79,"type":22},"2026-07-31",{"date":81,"type":22},"2027-12-31",{"name":83,"class":84},"Canadian Cancer Trials Group","NETWORK",{"id":86,"slug":87,"hasResults":12,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":12,"sex":69,"minAge":18,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":94,"conditions":95,"keywords":104,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":126},"100630545","phase-2-symbiotic-lung-10-a-study-to-learn-about-pf-08634404-alone-or-in-combination-in-early-stage-or-locally-advanced-nsclc-100630545","NCT07489066","Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC","AN INTERVENTIONAL, OPEN-LABEL, PHASE 2 STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY OR IN COMBINATION IN ADULT PARTICIPANTS WITH EARLY-STAGE RESECTABLE OR LOCALLY ADVANCED UNRESECTABLE NON-SMALL CELL LUNG CANCER","Inclusion Criteria:\n\n* 18 years of age or older at screening.\n* Have tumor tissue available, either paraffin block or slides from a core, excisional or fine needle biopsy\n* PD-L1 status available based on local testing results\n* Adequate organ function\n* Eastern Cooperative Oncology Group performance status (ECOG) score of 0 or 1\n* Part A only: Participants must have newly diagnosed, previously untreated, pathologically confirmed early-stage or LA (Stage II or IIIA\u002FB), squamous or non-squamous NSCLC (according to the 9th edition of the Union for International Cancer Control and American Joint Committee on Cancer lung cancer TNM staging system) with disease that is considered resectable, as assessed by a multidisciplinary evaluation, which must include a thoracic surgeon who performs lung cancer surgery as a prominent part of his\u002Fher practice. The participant must be a candidate for neoadjuvant therapy followed by complete surgical resection.\n* Part B only: Participants must have pathologically confirmed early-stage or LA (Stage II or IIIA\u002FB), squamous or non-squamous NSCLC (according to the 9th edition of the Union for International Cancer Control and American Joint Committee on Cancer lung cancer TNM staging system) and have undergone complete surgical resection. The participant must be considered a candidate for adjuvant therapy and must not have achieved pCR with SOC neoadjuvant chemo-immunotherapy.\n* Part C only: Participants must have pathologically confirmed LA, unresectable (Stage III) squamous or non-squamous NSCLC (according to the 9th edition of the Union for International Cancer Control and American Joint Committee on Cancer lung cancer TNM staging system) and have received ≥ 60 Gy of radiation and ≥ 2 cycles of definitive, platinum-based concurrent chemotherapy and achieved SD or better per RECIST 1.1.\n\nExclusion Criteria:\n\n* Participants with known EGFR and ALK AGAs; documented negative results for EGFR and ALK AGAs are required for participants with non-squamous histology.\n* Participants with CNS lesions, including leptomeningeal metastasis, brainstem, meningeal, or spinal cord metastases or compression.\n* Participants with clinically significant risk of hemorrhage or fistula are excluded.\n* Participants with any history of another malignancy within 3 years before the first dose of study intervention, or any evidence of residual disease from a previously diagnosed malignancy.\n* Unresolved toxicities from prior anti-tumor therapy, that did not recover to NCI CTCAE v5.0 Grade 0 or 1.\n* Known to have a history of a severe allergy to any component of the study intervention, or a history of severe allergic reaction to chimeric or humanized antibody.\n* History of allogeneic organ \u002F hematopoietic stem cell transplantation.\n* Participants with any of the following respiratory conditions:\n\n  * Evidence of noninfectious or drug-induced interstitial lung disease (ILD) or pneumonitis\n  * Grade ≥3 pulmonary disease unrelated to underlying malignancy\n* History of uncontrolled comorbidities within 6 months prior to the first dose including uncontrolled cardiac and cerebrovascular conditions, hypertension, diabetes, significant vascular disease or arterial\u002Fsevere venous thromboembolic events.\n* Major surgery \\\u003C 4 weeks or minor surgery \\\u003C 3 days prior to first dose of study intervention.\n* History of severe bleeding tendency or coagulation dysfunction\n* History of esophageal varices, severe ulcers, unhealed wounds, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding within 6 months prior to the first dose.\n* Participants with acute, chronic or symptomatic infections including participants positive for active HIV, hepatitis B virus (HBV), or Hepatitis C virus (HCV).\n* Participants with history of immunodeficiency\n* Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation\u002Fbehavior (in the past 5 years) or laboratory abnormality that may increase the risk of study participation or make the participant inappropriate for the study.\n* Breastfeeding participants, participants of childbearing potential, and male participants who are unwilling to follow contraceptive measures.",{"count":71,"type":22},[25],"This study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well it works when given alone or with chemotherapy. The study is for adults with early stage or locally advanced non-small cell lung cancer (NSCLC) that may or may not be removable with surgery.\n\nThe study is seeking participants who:\n\n* Are aged 18 years or older\n* Have either:\n\n  * Early-stage or locally advanced (Stage II or IIIA\u002FB) NSCLC and are a candidate for neoadjuvant therapy, followed by surgical removal of the tumor. Neoadjuvant therapy is a treatment given as a first step to shrink the tumor before surgery.\n  * Early-stage or locally advanced (Stage II or IIIA\u002FB) NSCLC and are a candidate for adjuvant therapy and did not achieve a pathological complete response (pCR) from approved treatment that was administered before surgery. Adjuvant therapy is an additional cancer treatment given after the primary treatment to lower the risk that the cancer will come back. pCR is defined as absence of viable tumor in all surgically removed samples.\n  * Locally advanced (Stage III) NSCLC that may not be removable with surgery, was treated with concurrent chemoradiotherapy (cCRT), and is a candidate for additional treatment, otherwise known as consolidation therapy. cCRT is chemotherapy and radiation given simultaneously.\n* Be in good physical condition and have healthy organs based on medical tests.\n* Do not have known actionable changes in DNA\n\nThe study has 3 parts and each participant will be assigned to one part by their doctor based on their disease diagnosis:\n\n* Part A will test PF-08634404 given with chemotherapy in the neoadjuvant setting, followed by surgery.\n* Part B will test PF-08634404 alone in adults who already were treated with neoadjuvant chemo-immunotherapy, underwent surgery, and did not achieve pCR per tumor tissue pathology analysis. Neoadjuvant chemo-immunotherapy refers to the combination of chemotherapy with immunotherapy per local standard-of-care, given before surgical removal of the tumor.\n* Part C will test PF-08634404 alone in adults with unresectable disease who received cCRT and did not have progressive disease. Progressive disease refers to a condition that grows, spreads, or worsens.\n\nAll treatments will be done at clinical study sites, where a trained medical team will monitor adults during and after each visit.",[31,96,97,98,99,100,101,102,103],"Non-Small-Cell Lung","Lung Cancer (NSCLC)","Lung Neoplasms","Carcinoma, Non-Small-Cell Lung (NSCLC)","Lung Disease","Non-Small Cell Lung Cancer","Non-small Cell Lung Cancer, Non-squamous","Non-small Cell Lung Cancer, Squamous",[105,106,107,108,109,110,111,112,113,114],"early stage non small cell lung cancer","NSCLC","adjuvant NSCLC","locally advanced non small cell lung cancer","resectable NSCLC","unresectable NSCLC","neoadjuvant NSCLC","consolidation NSCLC","squamous NSCLC","non-squamous NSCLC","RECRUITING","2026-06-04",{"date":118,"type":40},"2026-06-08",{"date":120,"type":22},"2026-06-01",{"date":122,"type":22},"2031-07-30",{"name":124,"class":125},"Pfizer","INDUSTRY",3,{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":12,"sex":69,"minAge":4,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":23,"phases":136,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":48},"100431379","phase-1-b7-h3-specific-chimeric-antigen-receptor-autologous-t-cell-therapy-for-pediatric-patients-with-solid-tumors-3car-100431379","NCT04897321","B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)","Inclusion Criteria:\n\nProcurement and T-cell production eligibility\\*\n\n\\*a previously collected, autologous leukapheresis product can be used for T-cell production\n\n* Age ≤21 years old\n* B7-H3+ solid tumor with measurable disease; B7-H3 expression will be evaluated by standard immunohistochemistry (IHC) using a previously obtained biopsy; a tumor is considered B7-H3 positive with an H-score ≥100\n* Estimated life expectancy of \\>12 weeks\n* Karnofsky or Lansky (age-dependent) performance score ≥50\n* For females of child bearing age:\n* Not pregnant with negative serum pregnancy test within 7 days prior to enrollment\n* Not lactating with intent to breastfeed\n* Meets eligibility criteria to undergo autologous apheresis, or have previously undergone autologous apheresis\n\nExclusion Criteria:\n\n* Known primary immunodeficiency\n* Known HIV positivity\n* Severe intercurrent bacterial, viral or fungal infection (e.g. active hepatitis B or C infection or adenovirus infection)\n* History of hypersensitivity reactions to murine protein-containing products\n* Rapidly progressive disease (in the opinion of the study PIs)\n\nInclusion criteria\n\nTreatment eligibility\n\n* Age ≤21 years old\n* B7-H3+ solid tumor with measurable disease\n* Evidence of relapsed or refractory disease after standard first-line therapy\n* Estimated life expectancy of \\>8 weeks\n* Karnofsky or Lansky (age-dependent) performance score≥50\n* Echocardiogram with a ventricular ejection fraction\n* \\>40%; or shortening fraction ≥25%\n* Adequate renal function defined as creatinine clearance or radioisotope GFR 50 ml\u002Fmin\u002F1.73m2 (GFR 40 ml\u002Fmin\u002F1.73m2 if \\\u003C 2 years of age)\n* Adequate pulmonary function defined as pulse oximetry ≥92% on room air or forced vital capacity (FVC) ≥50% of predicted value\n* Total Bilirubin ≤3 times the upper limit of normal for age, except in subjects with Gilbert's syndrome\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤5 times the upper limit of normal for age\n* Hemoglobin≥ 7g\u002FdL (can be transfused)\n* Platelet count \\>50,000\u002FuL (can be transfused)\n* Absolute neutrophil count (ANC) ≥ 1000\u002FuL\n* Has recovered from all NCI CTAE grade III-IV, non-hematologic acute toxicities from prior therapy\n* For females of child bearing age:\n* Not pregnant with negative serum pregnancy test within 7 days prior to enrollment\n* Not lactating with intent to breastfeed\n* If sexually active, agreement to use birth control until 3 months after T-cell infusion. Male partners should use a condom.\n* Available autologous transduced T-cell product that has met GMP release criteria\n* Agreement to participate in long-term follow-up protocol for patients, who have received genetically modified cell products\n\nExclusion criteria\n\n* Known primary immunodeficiency\n* History of HIV infection\n* Severe, uncontrolled intercurrent bacterial, viral or fungal infection\n* History of hypersensitivity reactions to murine protein-containing products\n* Receiving systemic steroid therapy exceeding the equivalent of 0.5 mg\u002Fkg\u002Fday of methylprednisolone, in the 7 days prior to B7-H3-CAR T-cell infusion\n* Receiving systemic therapy in the 14 days prior to CAR T-cell infusion, which will interfere with the activity of the B7-H3-CAR product (in the opinion of the study PIs).\n* Rapidly progressing disease (in the opinion of the study PIs)","21 Years",{"count":135,"type":22},48,[137],"PHASE1","3CAR is being done to investigate an immunotherapy for patients with solid tumors. It is a Phase I clinical trial evaluating the use of autologous T cells genetically engineered to express B7-H3-CARs for patients ≤ 21 years old, with relapsed\u002Frefractory B7-H3+ solid tumors. This study will evaluate the safety and maximum tolerated dose of B7-H3-CAR T cells.The purpose of this study is to find the maximum (highest) dose of B7-H3-CAR T cells that are safe to give to patients with B7-H3-positive solid tumors.\n\nPrimary objective\n\nTo determine the safety of one intravenous infusion of autologous, B7-H3-CAR T cells in patients (≤ 21 years) with recurrent\u002Frefractory B7-H3+ solid tumors after lymphodepleting chemotherapy\n\nSecondary objective\n\nTo evaluate the antitumor activity of B7-H3-CAR T cells\n\nExploratory objectives\n\n* To evaluate the tumor environment after treatment with B7-H3-CAR T cells\n* To assess the immunophenotype, clonal structure and endogenous repertoire of B7-H3-CAR T cells and unmodified T cells\n* To characterize the cytokine profile in the peripheral blood after treatment with B7-H3-CAR T cells",[140,141,142,143,144,145,146,147,148,149,150,151,152,31,153,154],"Pediatric Solid Tumor","Osteosarcoma","Rhabdomyosarcoma","Neuroblastoma","Ewing Sarcoma","Wilms Tumor","Adrenocortical Cancer","Desmoplastic Small Round Cell Tumor","Germ Cell Cancer","Rhabdoid Tumor","Clear Cell Sarcoma","Hepatoblastoma","Melanoma","Malignant Peripheral Nerve Sheath Tumors","Soft Tissue Sarcoma","2026-05-18",{"date":157,"type":40},"2026-05-19",{"date":159,"type":40},"2022-07-06",{"date":161,"type":22},"2028-03-01",{"name":163,"class":164},"St. Jude Children's Research Hospital","OTHER",{"id":166,"slug":167,"hasResults":12,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":23,"phases":175,"briefSummary":177,"conditions":178,"keywords":180,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":48},"100637594","impact-of-body-composition-on-dosimetry-of-177lu-psma-radioligand-therapy-100637594","NCT07587814","Impact of Body Composition on Dosimetry of 177Lu-PSMA Radioligand Therapy","Impact de la Composition Corporelle Sur la dosimétrie de la radiothérapie Interne vectorisée au 177Lu-PSMA","COCORIVO","Inclusion Criteria:\n\n* Signed informed consent\n* Male, age \\>= 18 years\n* Histologically confirmed prostatic adenocarcinoma with multidisciplinary decision for 177Lu-PSMA treatment\n* PSMA expression in tumor lesions confirmed by 68Ga-PSMA PET\u002FCT\n* Affiliated to or beneficiary of a social security scheme\n\nExclusion Criteria:\n\n* Patient unable to understand the study or comply with study constraints (language barrier, psychological, geographic...)\n* Patient under legal protection (tutelle, curatelle, sauvegarde de justice)",{"count":174,"type":22},100,[176],"NA","COCORIVO is an interventional study evaluating the impact of body composition on dosimetry of 177Lu-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). Body composition (muscle, lean, visceral fat, subcutaneous fat and total fat masses) will be automatically quantified from whole-body CT images acquired at 72-96h after 177Lu-PSMA injection using the Anthropometer3DNet software. Dosimetry will be evaluated for tumors and organs at risk (salivary glands, bone marrow, kidneys). The study also evaluates the impact of body composition on SUV quantification, the feasibility of single-timepoint dosimetry, and the evolution of body composition during treatment.",[31,179],"Castration Resistant Prostatic Neoplasms",[181,182,183,184,185,186],"Lutetium-177","PSMA","Body composition","Dosimetry","Radioligand therapy","Prostate cancer","2026-05-11",{"date":189,"type":40},"2026-05-14",{"date":191,"type":22},"2026-09",{"date":193,"type":22},"2029-06",{"name":195,"class":164},"Centre Henri Becquerel",{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":12,"sex":69,"minAge":18,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":23,"phases":205,"briefSummary":206,"conditions":207,"keywords":209,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":222},"100550287","phase-2-using-circulating-tumor-dna-to-risk-adapt-post-operative-therapy-for-hpv-associated-oropharyngeal-cancer-100550287","NCT06445114","Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer","ULTRA-HPV Using Circulating Tumor DNA to Risk Adapt Post-operative Therapy for HPV Associated Oropharyngeal Cancer","Inclusion Criteria:\n\n* AJCC 8th edition T0-3N0-2 p16-positive oropharyngeal (tonsil, base of tongue, glossotonsillar sulcus, soft palate, oropharyngeal wall) squamous cell carcinoma or squamous cell carcinoma of unknown primary involving the cervical lymph nodes. Cytologic diagnosis from a cervical lymph node is sufficient for diagnosis in the presence of clinical evidence of a primary tumor in the oropharynx.\n* For patients with pT0 tumors (unknown primary), there must be at least one metastatic lymph node present in cervical level II.\n* p16 is strongly positive by immunohistochemistry or high-risk HPV is detected by in-situ hybridization.\n* Have undergone or will undergo gross total resection of all known disease in the head and neck via transoral robotic surgery. For patients with clinical unknown primary tumors, a patient must undergo both ipsilateral tonsillectomy and base of tongue resection unless the primary is identified clinically or pathologically at the time of surgery. If the primary is identified, then only resection of the primary site is required. If the primary tumor is resected with negative margins with a non-robotic surgery, such as a diagnostic tonsillectomy, this is considered acceptable and further robotic surgery is not necessary.\n* Have undergone or will undergo neck dissection.\n* Have at least one of the following after surgery:\n\n  * Pathologic stage T3\n  * 2 or more positive lymph nodes\n  * At least one lymph node \\>3cm\n  * Contralateral lymph node involvement\n  * Lymphovascular invasion\n  * Perineural invasion\n  * Extranodal extension\n  * Close\u002Fpositive margins: Close margins are considered ≤3mm from the peripheral margins and ≤1mm from the deep margin on the en bloc specimen, unless the area of close margin is re-resected and without carcinoma.\n* Patients consented preoperatively are required to have detectable cTTMV-HPV DNA based on pre-operative NavDx testing. For patients consented post-operatively, NavDx testing should be performed on the tumor tissue to ensure detectable HPV DNA and for HPV subtyping.\n* Age ≥ 18 years old\n* ECOG performance status 0 or 2 within 56 days of start of chemoradiation.\n* Women of childbearing potential require a negative serum or urine pregnancy test within 28 days prior to start of chemoradiation.\n* Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.\n* Adequate hematologic and renal function within 56 days of start of chemoradiation, defined as:\n\n  * Hemoglobin ≥ 9.0 g\u002FdL\n  * Platelets ≥ 100, 000 cells\u002Fmm3\n  * ANC ≥ 1.5 X 109\u002FL\n  * Total bilirubin ≤ 1.5 x upper limit of normal (ULN)\n  * Aspartate aminotransferase\u002Falanine aminotransferase ≤ 3.0 x upper limit of normal (ULN)\n  * Serum creatinine ≤1.5 x upper limit of normal (ULN) OR a calculated creatinine clearance ≥50 mL\u002Fmin estimated using the following Cockcroft-Gault equation\n\nExclusion Criteria:\n\n* AJCC 8th edition pT4 or cN3 disease.\n* Radiologic or clinical evidence of distant metastasis.\n* Recurrent disease.\n* Inability to achieve gross total resection at time of surgery.\n* Greater than 56 days (8 weeks) after surgical resection of the primary site.\n* Prior radiation to the head and neck \\> 30 Gy.\n* Prior active invasive (not in situ) malignancy within the prior 2 years, excluding cutaneous basal cell or squamous cell carcinoma, low or intermediate risk prostate cancer, papillary thyroid cancer, stage T1aN0 kidney cancer, low-grade T1-2N0 salivary cancer, AJCC 8th edition stage I-II breast cancer, well-differentiated neuroendocrine tumors (e.g., carcinoid tumors), low grade non-Hodgkin lymphoma, or Stage 0, I, and III cutaneous melanomas. Patients with synchronous or multifocal oropharyngeal cancers are not excluded, as long as at least one of these tumors meet inclusion criteria for the trial.\n* Severe, active co-morbidity, defined as follows:\n\n  * Unstable angina and\u002For congestive heart failure requiring hospitalization within the last 6 months\n  * Transmural myocardial infarction within the last 6 months\n  * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of enrollment\n  * Hepatic insufficiency resulting in clinical jaundice and\u002For known coagulation defects\n* Moderate to severe hearing loss.\n* Active connective tissue disease (e.g. systemic lupus erythematous, scleroderma) requiring immunosuppression.\n* Pregnant or breast-feeding women.\n* Prior allergic reaction to cisplatin.\n* Live vaccines within 30 days prior to the first dose of chemoradiation. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, BCG, and typhoid (oral vaccine). Season influenza vaccines for injection are generally killed virus vaccines and are allowed; however intranasal influenza vaccines (e.g. Flu-Mist®) are live attenuated vaccines and are not allowed.",{"count":204,"type":22},50,[25],"This is a single institution phase II study that will enroll patients with T0-3N0-2 p16-positive oropharyngeal squamous cell carcinoma (OSCC) undergoing resection of all gross visible disease at the primary site and in the lymph nodes.",[208,31],"Oropharyngeal Cancer",[210,211,212],"Transoral Robotic Surgery (TORS)","pT0 tumors (unknown primary)","p16","2026-05-05",{"date":215,"type":40},"2026-05-08",{"date":217,"type":40},"2025-05-12",{"date":219,"type":22},"2032-06",{"name":221,"class":164},"Zachary Zumsteg",4,{"id":224,"slug":225,"hasResults":12,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":231,"sex":69,"minAge":18,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":234,"conditions":235,"keywords":246,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":48},"100621015","mrinrt-swansea-university-and-swwcc-collaboration-study-100621015","NCT07365124","MRinRT: Swansea University and SWWCC Collaboration Study.","Developing and Optimising the Use of Magnetic Resonance Imaging and Spectroscopy in Radiotherapy (MRinRT) Pathways: Investigating Avenues to Improve Outcomes for Patients and the Assessment of Treatment Response.","MRinRT","Inclusion Criteria for health volunteers:\n\n* Free from medical conditions that could confound imaging or study results\n* Eligible for MRI\n\nInclusion Criteria for patients:\n\n* Confirmed diagnosis of invasive carcinoma at the relevant tumour\u002Ftarget sites listed in this protocol\n* Scheduled to receive radiotherapy to the target site\n* ECOG performance status of 0-2\n* Eligible for MRI (determined through MRI safety screening)\n\nExclusion Criteria:\n\n* Presence of medical conditions that may interfere with study outcomes or data interpretation\n* Use of regular medications that could affect imaging results or safety\n* Any contraindications to MRI scanning, including but not limited to claustrophobia, reduced thermal regulatory capabilities, MR Unsafe implants and foreign bodies.",true,{"count":233,"type":22},165,"The aim of this study is to learn whether using MRI (magnetic resonance imaging) scans to plan radiotherapy is better than using CT (computed tomography) scans alone. The main questions it aims to answer is:\n\n* Can MRI scan images be adjusted to make the tumour and normal tissues easier to see?\n* Does adding MRI to a radiotherapy planning CT make the radiotherapy plan more precise?\n* Can MRI be used to adjust a radiotherapy plan during a course of treatment to make it more precise, and might that reduce the side effects?\n* Are there particular MRI scans that can predict how a tumour will respond to radiotherapy or how likely the patient is to have side effects?\n\nThis study will assess current MRI scanning procedures and ensure these are adjusted to best suit radiotherapy planning. It will also provide pilot data evaluating:\n\n1. MRI-adapted radiotherapy Usually, radiotherapy plans are based on a pre-treatment planning CT scan. Unless an issue is detected the patient would complete their whole course of radiotherapy on this plan. This does not account for changes in position\u002Fsize\u002Fshape of the tumour that occur over the whole treatment course. Clinicians therefore increase the size of the tumour\u002Ftarget to account for these uncertainties, which can increase side effects. This study will assess the potential to reduce side effects from radiotherapy by using repeat MRI scans and replanning during the treatment course (MRI-adaptive radiotherapy).\n2. Imaging biomarkers MRI sequences can be used to predict response to radiotherapy or chance of developing side effects. This study will identify potential MRI sequences that may be used as imaging biomarkers, to guide the development of future clinical trials.\n\nThe study will be undertaken at SBUHB, lasting 4 years, and involving ≤15 healthy volunteers and ≤150 patients.",[31,236,237,238,239,240,241,242,243,244,245],"Glioblastoma","Radiotherapy","MRI","MRI-guided Adaptive Radiotherapy","MRI Scanner Configuration","MRI Image Enhancement","Oesophageal Carcinoma","Pancreas Carcinoma","Gastric Cancer","Brain (Nervous System) Cancers",[238,237,247,248],"MRI adaptive radiotherapy","MRI Imaging Biomarker","2026-04-29",{"date":251,"type":40},"2026-04-30",{"date":253,"type":22},"2026-05",{"date":255,"type":22},"2032-01",{"name":257,"class":164},"Swansea Bay University Health Board",{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":12,"sex":265,"minAge":18,"maxAge":4,"enrollmentInfo":266,"targetDuration":4,"studyType":23,"phases":268,"briefSummary":269,"conditions":270,"keywords":274,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":48},"100482273","phase-1-cabozantinib-and-dostarlimab-in-recurrent-gynecologic-carcinosarcoma-100482273","NCT05559879","Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma","A Phase Ib\u002FII Single Arm Study of Cabozantinib Plus Dostarlimab in Women With Recurrent Gynecologic Carcinosarcoma","Inclusion Criteria:\n\n1. Histologically confirmed diagnosis of carcinosarcoma (independent of organ of gynecologic origin)\n2. Received at least one prior chemotherapy regimen for their cancer\n3. Must have measurable or evaluable lesion defined by iRECIST\n4. Recovery to baseline or ≤ Grade 1 CTCAE v5.0 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and\u002For stable on supportive therapy\n5. ECOG Performance Status of 0-2\n6. Age ≥ 18 years\n7. Adequate organ and marrow function, based upon meeting all of the following laboratory criteria within 14 days before first dose of study treatment:\n\n   1. Absolute neutrophil count (ANC) ≥ 1500\u002Fmm3 (≥ 1.5 GI\u002FL) without granulocyte colony-stimulating factor support.\n   2. White blood cell count ≥ 2500\u002Fmm3 (≥ 2.5 GI\u002FL).\n   3. Platelets ≥ 100,000\u002Fmm3 (≥ 100 GI\u002FL) without transfusion.\n   4. Hemoglobin ≥ 9 g\u002FdL (≥ 90 g\u002FL).\n   5. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) ≤ 3 x upper limit of normal (ULN). ALP ≤ 5 x ULN with documented bone metastases.\n   6. Total bilirubin ≤ 1.5 x ULN (for patients with Gilbert's disease ≤ 3 x ULN).\n   7. Serum albumin ≥ 2.8 g\u002Fdl.\n   8. Serum creatinine ≤ 2.0 x ULN or calculated creatinine clearance ≥ 30 mL\u002Fmin (≥ 0.5 mL\u002Fsec) using the Cockcroft-Gault equation:\n\n   \\[(140 - age) x weight (kg)\u002F(serum creatinine \\[mg\u002FdL\\] × 72)\\] × 0.85 i. Urine protein\u002Fcreatinine ratio (UPCR) ≤ 1 mg\u002Fmg (≤ 113.2 mg\u002Fmmol).\n8. Capable of understanding and complying with the protocol requirements and must have signed the informed consent document.\n9. Women of childbearing potential (WOCBP) ie. sexually active fertile patients and their partners must agree to use medically accepted methods of contraception (e.g., barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 5 months after the last dose of study treatment.\n10. Females should not breastfeed while receiving treatment on trial.\n11. Female patients of childbearing potential must not be pregnant at screening. Females of childbearing potential are defined as premenopausal females capable of becoming pregnant (i.e., females who have had any evidence of menses in the past 12 months, with the exception of those who had a prior hysterectomy). However, women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, low body weight, ovarian suppression, or other reasons.\n\nExclusion Criteria:\n\n1. Prior treatment with cabozantinib.\n2. Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks or 5 half-lives (whichever is longer) before first dose of study treatment.\n3. Receipt of any type of cytotoxic, biologic, or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study treatment.\n4. Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment. Systemic treatment with radionuclides within 6 weeks before the first dose of study treatment. Patients with clinically relevant ongoing complications from prior radiation therapy are not eligible.\n5. Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and\u002For surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment. Eligible patients must be neurologically asymptomatic and without corticosteroid treatment at the time of first dose of study treatment.\n6. Concomitant anticoagulation with coumarin agents (e.g., warfarin), direct thrombin inhibitors (e.g., dabigatran), direct factor Xa inhibitor betrixabin, or platelet inhibitors (e.g., clopidogrel). Allowed anticoagulants are the following:\n\n   1. Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH).\n   2. Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban in subjects without known brain metastases who are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor.\n7. The patient has prothrombin time (PT)\u002FINR or partial thromboplastin time (PTT) test ≥ 1.3 X the laboratory ULN within 7 days before the first dose of study treatment.\n8. The patient has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:\n\n   a. Cardiovascular disorders: i. Congestive heart failure New York Heart Association Class 3 or 4, unstable angina pectoris, serious cardiac arrhythmias.\n\n   ii. Uncontrolled hypertension defined as sustained blood pressure (BP) \\> 140 mm Hg systolic or \\> 90 mm Hg diastolic despite optimal antihypertensive treatment.\n\n   iii. Stroke (including transient ischemic attack \\[TIA\\]), myocardial infarction (MI), or other ischemic event, or thromboembolic event (e.g., deep venous thrombosis, pulmonary embolism) within 6 months before first dose.\n\n   b. Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation: i. The patient has evidence of tumor invading the GI tract, active peptic ulcer disease, inflammatory bowel disease (e.g., Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis, acute obstruction of the pancreatic duct or common bile duct, or gastric outlet obstruction.\n\n   ii. Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess within 6 months before first dose.\n\n   Note: Complete healing of an intra-abdominal abscess must be confirmed before first dose.\n\n   c. Clinically significant hematuria, hematemesis, or hemoptysis of \\> 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (e.g., pulmonary hemorrhage) within 12 weeks before first dose.\n\n   d. Cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease manifestation.\n\n   e. Lesions invading or encasing any major blood vessels. f. Other clinically significant disorders that would preclude safe study participation.\n\n   i. Serious non-healing wound\u002Fulcer\u002Fbone fracture ii. Uncompensated\u002Fsymptomatic hypothyroidism (i.e. inadequately treated hypothyroidism) iii. Moderate to severe hepatic impairment (Child-Pugh B or C)\n9. Major surgery (e.g., laparoscopic nephrectomy, GI surgery, removal or biopsy of brain metastasis) within 2 weeks before first dose of study treatment. Minor surgeries within 10 days before first dose of study treatment. Subjects must have complete wound healing from major surgery or minor surgery before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior surgery are not eligible.\n10. Corrected QT interval calculated by the Fridericia formula (QTcF) \\> 500 ms per electrocardiogram (ECG) within 28 days before first dose of study treatment \\[add reference for Fridericia formula\\].\n\n    Note: If a single ECG shows a QTcF with an absolute value \\> 500 ms, two additional ECGs at intervals of approximately 3 min must be performed within 30 min after the initial ECG, and the average of these three consecutive results for QTcF will be used to determine eligibility.\n11. Inability to swallow tablets.\n12. Previously identified allergy or hypersensitivity to components of the study treatment formulations.\n13. Diagnosis of another malignancy within 2 years before first dose of study treatment, except for superficial skin cancers, or localized, low-grade tumors deemed cured and not treated with systemic therapy.\n14. Patients with concurrent cytotoxic chemotherapy or radiation therapy are excluded.\n15. Patients with a serious chronic or acute illness, such as cardiac disease (NYHA class III or IV), hepatic disease, or other illness considered by the Principal Investigator as unwarranted high risk for investigational drug treatment.\n16. Patients with a medical or psychological impediment to probable compliance with the protocol should be excluded.\n17. Presence of a known active acute or chronic infection including: a urinary tract infection, HIV or viral hepatitis; however, it is acceptable to treat an acute infection and then re-screen or re-evaluate eligibility.\n18. Administration of a live, attenuated vaccine within 30 days prior to first dose of study treatment\n19. Other clinically significant disorders:\n\n    1. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.\n    2. Active, known, or suspected autoimmune disease (exceptions: type 1 diabetes mellitus, hypothyroidism, skin disorders, conditions not expected to recur in the absence of an external trigger)\n    3. Malabsorption syndrome\n    4. Requirement for hemodialysis or peritoneal dialysis\n    5. History of solid organ or allogenic stem cell transplant","FEMALE",{"count":267,"type":22},37,[137,25],"Immunotherapy has gained a significant amount of attention recently, but its efficacy as a single agent in gynecological cancers has been disappointing. Pre-clinical evidence supports the combination of using Vascular Endothelial Growth Factors (VEGF) inhibitors with immunotherapy. VEGF inhibitors suppress the activation of tumor-associated macrophages (TAMs) and VEGF has been shown to affect the functional maturation of dendritic cells; therefore, VEGF inhibitors could improve the function of antigen presentation. In this study, Cabozantinib (VEGF inhibitor) and Dostarlimab (immunotherapeutic drug) will be admnistered as a combination to patients with recurrent gynecologic carcinosarcoma.",[271,31,272,273],"Gynecologic Cancer","Uterine Cancer","Endometrial Cancer",[271,31,272,273],"2026-04-10",{"date":277,"type":40},"2026-04-15",{"date":279,"type":40},"2023-08-20",{"date":281,"type":22},"2027-04",{"name":283,"class":164},"University of Alabama at Birmingham",{"id":285,"slug":286,"hasResults":12,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":12,"sex":69,"minAge":18,"maxAge":4,"enrollmentInfo":291,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":293,"conditions":294,"keywords":295,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":312},"100612708","nasal-reconstruction-face-q--french-validation-of-the-nasal-reconstruction-face-q-questionnaire-for-reconstructionrehabilitation-following-nasal-skin-cancer-100612708","NCT07257094","Nasal Reconstruction FACE-Q : French Validation of the Nasal Reconstruction FACE-Q Questionnaire for Reconstruction\u002FRehabilitation Following Nasal Skin Cancer","French Validation of the Nasal Reconstruction FACE-Q Questionnaire for Reconstruction\u002FRehabilitation Following Nasal Skin Cancer","PATIENTS\n\nInclusion Criteria\n\n* Age ≥ 18 years\n* Patient who has undergone excision of a cutaneous, mucocutaneous, or vestibular nasal cancer with surgical reconstruction using a flap or prosthetic rehabilitation, performed more than 4 months ago, with stable results, and less than 3 years ago\n* Patient informed of the study and not opposed to participation\n\nExclusion Criteria\n\n* Patient under anticoagulant or antiplatelet therapy Non-French-speaking patient\n* Patient under legal protection (e.g., guardianship, legal safeguard) or with limited legal capacity\n* Patient unlikely to cooperate with the study and\u002For poor anticipated compliance as judged by the investigator (including psychiatric disorders other than depressive disorder or cognitive impairment)\n* Pregnant or breastfeeding woman\n\nCONTROL\n\nInclusion Criteria\n\n* Age ≥ 65 years\n* Subject informed and not opposed to participating in the study\n* Subject who has never undergone facial trauma or surgery, and without major comorbidity, defined as follows:\n* No heart failure (moderate or severe heart failure, history of heart attack within the last 6 months);\n* No severe chronic respiratory disease (no stage III-IV COPD, no prolonged oxygen therapy);\n* No uncontrolled diabetes or associated severe complications;\n* No active immunosuppressive diseases or high-dose immunosuppressive treatment;\n* No unstable or severe facial dermatological conditions;\n* No comorbidities seriously affecting quality of life or respiratory function (at the investigator's discretion).\n\nExclusion Criteria\n\n* Non-English speaking subject\n* Subject under guardianship or legal protection, legally incompetent or with limited legal capacity\n* Subject unlikely to cooperate in the study and\u002For anticipated low cooperation by the investigator (particularly those with psychiatric disorders other than depression or cognitive disorders)\n* Pregnant or breastfeeding women",{"count":292,"type":22},346,"This study aims to validate a French version of the Nasal Reconstruction FACE-Q questionnaire for patients who have undergone nasal reconstruction or prosthetic rehabilitation after surgery for nasal skin cancer. The questionnaire evaluates appearance, quality of life, and possible side effects related to the reconstruction.\n\nThe investigators hypothesize that the validated French version will provide a reliable and standardized tool to assess patient satisfaction and health-related quality of life in this context.",[31],[296,297,298,299,300,301,302],"Basal Cell carcinoma","Squamous Cell carcinoma","Rhinectomy","Reconstructive Surgical Procedures","Prosthesis Implantation","FACE-Q","Quality of Life","2026-03-26",{"date":305,"type":40},"2026-03-31",{"date":307,"type":40},"2026-01-10",{"date":309,"type":22},"2027-07-30",{"name":311,"class":164},"Hôpital NOVO",9,{"id":314,"slug":315,"hasResults":12,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":12,"sex":69,"minAge":18,"maxAge":4,"enrollmentInfo":320,"targetDuration":4,"studyType":23,"phases":321,"briefSummary":323,"conditions":324,"keywords":326,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":48},"100444308","early-phase-1-using-a-pet-imaging-agent-18f-clofarabine-cfa-to-measure-deoxycytidine-kinase-activity-in-metastatic-cancer-100444308","NCT05065736","Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer","18F-Clofarabine (CFA) as a PET Imaging Agent to Measure Deoxycytidine Kinase (DCK) Activity in Metastatic Cancer, as a Candidate Predictive Biomarker for Response to DCK-dependent Drugs Such as Gemcitabine","Inclusion Criteria:\n\n* Histologically or cytologically proven metastatic cancer (including carcinoma, adenocarcinoma, sarcoma, or neuroendocrine cancer).\n* Subjects must have metastatic disease, confirmed by imaging, typically a CT scan of the chest\u002Fabdomen\u002Fpelvis.\n* Subjects must have measurable disease per RECIST 1.1\n* Over 18 years of age\n* ECOG performance status 0-1\n* Adequate organ function as defined by the following criteria (labs may be no more than 4 weeks prior to the screening date):\n\n  * Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase \\[SGOT\\]) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase \\[SGPT\\]) \\\u003C= 2.5 x laboratory upper limit of normal (ULN)\n  * Total serum bilirubin \\\u003C= 2.0 x ULN\n  * Absolute neutrophil count (ANC) \\>= 1500\u002FuL\n  * Platelets \\>= 75,000\u002FuL\n  * Hemoglobin \\>= 8.0 g\u002FdL\n  * Serum calcium \\\u003C= 12.0 mg\u002FdL\n  * Serum creatinine \\\u003C= 2.9 mg\u002FdL\n* Subjects must have the ability to understand and the willingness to sign a written informed consent document\n* Patient is able to remain still for the duration of the imaging procedure (up to one hour).\n\nExclusion Criteria:\n\n* Within 6 months prior to enrollment on this study: myocardial infarction, severe\u002Funstable angina, severe peripheral vascular disease (claudication) or procedure on peripheral vasculature, coronary\u002Fperipheral artery bypass graft, New York Heart Association grade II or greater congestive heart failure, cerebrovascular accident or transient ischemic attack, clinically significant bleeding or pulmonary embolism.\n* Pregnancy or breastfeeding (pregnant or breastfeeding women are excluded from this study because study drugs have the potential for teratogenic or abortifacient effects.\n* Other severe acute or chronic medical or psychiatric conditions or laboratory abnormalities that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study.",{"count":222,"type":22},[322],"EARLY_PHASE1","The purpose of this study is to evaluate whether a new type of imaging study, called 18F-Clofarabine (CFA) PET\u002FCT, can be used to image cancer pyrimidine metabolism in participants.\n\nPET (positron emission tomography) imaging is a way of looking at cancers that can reveal cancer metabolism. Presently, however, there are no imaging agents in routine use to look at an aspect of cancer metabolism (pyrimidine metabolism) that dictates whether certain cancer drugs, e.g., gemcitabine, are likely to be taken into the cancer cells. This clinical trial will be testing whether 18F-Clofarabine (CFA) could be an imaging agent to measure this aspect of cancer metabolism.",[325,31,28],"Metastatic Cancer",[327,328,329],"18F-Clofarabine","Diagnostic Imaging","Cancer","2026-03-17",{"date":332,"type":40},"2026-03-19",{"date":334,"type":40},"2023-03-06",{"date":336,"type":22},"2026-06",{"name":338,"class":164},"Roberto Vargas",{"id":340,"slug":341,"hasResults":12,"nctId":342,"briefTitle":343,"officialTitle":343,"acronym":344,"eligibilityCriteria":345,"healthyVolunteers":12,"sex":69,"minAge":18,"maxAge":19,"enrollmentInfo":346,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":348,"conditions":349,"keywords":350,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":364},"100525946","anatomical-clinical-base-of-adenocarcinoma-pancreatic-100525946","NCT06128343","Anatomical-Clinical Base of Adenocarcinoma Pancreatic","BACAP-2","Inclusion Criteria:\n\n* Patient with pancreatic mass syndrome explored by ultrasound endoscopy with cytopuncture or\n* Patient with pancreatic mass syndrome explored by an abdominal scanner with and without injection of product contrast and\u002For puncture of the mass or secondary lesions by radiological route or\n* Patient with pancreatic adenocarcinoma proven histologically and\u002For cytologically\n\nExclusion Criteria:\n\n* Patient with a pancreatic tumor whose analysis histological is not an adenocarcinoma\n* Pregnant or breastfeeding patient",{"count":347,"type":22},1500,"BACAP-2 is a prospective biobank dedicated to the pancreatic adenocarcinoma including clinical data and biological samples from tumor. The aim is to enrich the previous propective collection BACAP in order to support future research projects.",[28,31,30],[28,351,352,353,354,355],"fine-needle aspiration","endoscopic ultrasonography","epidemiology","biobank","DNA tumors","2026-03-16",{"date":332,"type":40},{"date":359,"type":40},"2023-11-16",{"date":361,"type":22},"2035-02-28",{"name":363,"class":164},"University Hospital, Toulouse",8,{"id":366,"slug":367,"hasResults":12,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":371,"eligibilityCriteria":372,"healthyVolunteers":12,"sex":265,"minAge":18,"maxAge":4,"enrollmentInfo":373,"targetDuration":375,"studyType":72,"phases":4,"briefSummary":376,"conditions":377,"keywords":383,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":48},"100449245","registry-platform-ovarian-and-endometrial-cancer-100449245","NCT05129969","Registry Platform Ovarian and Endometrial Cancer","SMARAGD - Clinical Research Platform on Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancer Treatment and Outcomes","SMARAGD","Inclusion Criteria:\n\n* Confirmed high grade OC (advanced or metastatic epithelial ovarian, fallopian tube and primary peritoneal cancer):\n\n  * patients with FIGO stage IIb-IV OC who are starting systemic treatment or\n  * patients with recurrent\u002Frelapsed disease, who received any previous systemic anti-tumor treatment and who are now starting systemic treatment for recurrent\u002Frelapsed disease.\n* Locally advanced and inoperable or metastatic EC (FIGO stage III-IV) who are starting systemic first-line therapy.\n* Signed and dated informed consent (IC):\n\n  * Patients participating in PRO module: IC before first therapy cycle\n  * Patients not participating in PRO module: IC no later than six weeks after start of first therapy cycle\n\nExclusion Criteria:\n\n* newly diagnosed early-stage OC (FIGO stage I-IIa)\n* Low grade mOC OR\n* Early-stage EC (FIGO stage I-II)",{"count":374,"type":22},1975,"3 Years","The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with advanced or metastatic ovarian cancer (OC) or advanced or metastatic endometrial cancer (EC) in Germany.",[378,273,379,380,381,31,382],"Ovarian Cancer","Ovary Neoplasm","Endometrial Neoplasms","Carcinoma, Ovarian","Neoplasm, Ovarian",[384,385,386,387,388,389],"Registry","Health service research","Epidemiology","Germany","Palliative treatment","Palliative care","2026-01-26",{"date":392,"type":40},"2026-01-28",{"date":394,"type":40},"2021-11-25",{"date":396,"type":22},"2030-12",{"name":398,"class":125},"iOMEDICO AG",{"id":400,"slug":401,"hasResults":12,"nctId":402,"briefTitle":403,"officialTitle":404,"acronym":4,"eligibilityCriteria":405,"healthyVolunteers":12,"sex":69,"minAge":18,"maxAge":4,"enrollmentInfo":406,"targetDuration":4,"studyType":23,"phases":408,"briefSummary":409,"conditions":410,"keywords":412,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":423},"100461022","phase-2-study-to-evaluate-the-safety-and-efficacy-of-oral-nrc-2694-a-in-combination-with-paclitaxel-in-patients-with-recurrent-andor-metastatic-head-and-neck-squamous-cell-carcinoma-who-progressed-on-or-after-immune-checkpoint-inhibitor-therapy-100461022","NCT05283226","Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and\u002For Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy","A Phase 2 Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and\u002For Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy","Inclusion Criteria:\n\n* Is willing and capable of understanding the written informed consent, provides signed and witnessed written informed consent, and agrees to comply with protocol requirements.\n* Is male or female aged 18 years or older at the time of consent.\n* Has histologically confirmed unresectable R\u002FM HNSCC (oral cavity, oropharynx, hypopharynx, and larynx).\n* Has documented progressive disease assessed by the principal investigator according to RECIST v1.1.\n* Has a measurable lesion per RECIST v1.1.\n* Has ECOG performance status score of ≤2.\n* Must have progressed during or after receiving ICI therapy, such as pembrolizumab or nivolumab. Patients with prior immune-mediated reactions due to ICI therapies (eg, pembrolizumab or nivolumab) and who had recovered prior to study entry will also be eligible.\n* Female patients of childbearing potential should have a negative urine test before enrollment. If the urine pregnancy test is positive or gives equivocal results, a serum pregnancy will be required for confirmation.\n* Patients of reproductive age must use acceptable methods of contraception throughout the study period and for 30 days following the last dose of investigational product (see protocol for further guidance).\n* During screening and at subsequent visits, the investigator should ensure adequate bone marrow reserve (neutrophil count ≥1500\u002Fmm3, platelet count ≥100,000\u002Fmm3, and hemoglobin level 8.0 g\u002FdL), renal function (creatinine clearance ≥30 mL\u002Fmin calculated by Cockcroft-Gault formula), liver function (total bilirubin level ≤1.5 × ULN \\[except patients with documented Gilbert's syndrome\\] and serum transaminase levels ≤2.5 × ULN or ≤5 × ULN for liver metastasis and\u002For obstructive jaundice).\n* Must have completed a duration of at least two weeks after stopping ICI therapy\u002Finvestigational therapy\u002Fsalvage therapy and must have recovered to grade ≤1 from all toxicities due to such therapies.\n\nExclusion Criteria:\n\n* Has cardiac, hepatic, endocrine, pulmonary, or autoimmune disease, interstitial lung disease, renal or psychiatric disorders, not controlled with therapy corresponding to the illness or a condition that contraindicates the use of a taxane or an EGFR inhibitor.\n* Has Cirrhosis of liver at a level of Child-Pugh B (or worse).\n* Has uncontrolled brain metastases. Patients are allowed if brain metastasis has been previously treated with surgery, whole brain irradiation, and\u002For stereotactic radiosurgery and are considered controlled (controlled by the dose ≤10 mg\u002Fday of prednisone or equivalent) at the time of the first dose of investigational product. Radiological evaluation of brain metastasis will be performed only if the patient has symptoms. For asymptomatic patients, brain imaging during screening is not required.\n* Has baseline prolongation of QT\u002FQTc interval (eg, repeated demonstration of a QTc interval \\>480 milliseconds \\[CTCAE Grade 1\\] using Fredericia's QT correction formula).\n* Has a history of additional risk factors for Torsade de pointes (eg, heart failure, hypokalemia, family history of long QT syndrome).\n* Has had prior cetuximab therapy for recurrent or metastatic disease. Note that cetuximab used concomitantly with radiotherapy or as an induction therapy is acceptable\n* Has received any other EGFR-targeted therapies for recurrent or metastatic disease.\n* Currently participating in any clinical trial or receiving investigational therapy on expanded access or compassionate basis.\n* Has nasopharyngeal carcinomas or salivary gland cancers.\n* Female patient who tested positive for pregnancy.\n* Female patient who is breastfeeding or planning to become pregnant, or male patient planning to father a child within the duration of the study.\n* Has tested positive for HIV, HBsAg, HCV antibody, or HCV RNA at screening. However, patients who test positive for HCV antibody, but negative for HCV RNA, will be allowed. In addition, patients with controlled HIV, chronic HBV on suppressive antiviral therapy, or a history of HCV infection status post-curative antiviral treatment with an HCV viral load below limit of quantification are permitted to participate (DHHS 2020).\n* Has active infection requiring intravenous anti-infective therapy within 7 days prior to Day 1 Cycle 1 or is febrile due to infection.\n* Has had major surgery within 4 weeks prior to screening.\n* Administered a live attenuated vaccine within 4 weeks prior to Day 1 Cycle 1 or anticipation that such a live attenuated vaccine will be required during the study.\n* Has known or suspected hypersensitivity to any components of the formulation used for this investigational product.\n* Has concurrent disease or any clinically significant abnormality following the investigator's review of the screening physical examination findings, 12-lead ECG results, and clinical laboratory tests, which in the judgment of the investigator would interfere with the patient's participation in this study or evaluation of study results.\n* Unable to come for study visits per schedule.\n* Has current drug or alcohol abuse.\n* Has received prior treatment with paclitaxel or docetaxel or any other drugs with taxane like mode of action for recurrent or metastatic or recurrent HNSCC. However, prior paclitaxel or docetaxel or any other drugs with taxane like mode of action as a component of a curatively-intended multimodality treatment for locally advanced HNSCC is permitted.",{"count":407,"type":22},21,[25],"This is a Phase 2, open-label, multicenter, single-arm study of NRC-2694-A in combination with paclitaxel in patients with R\u002FM HNSCC with progression on or after ICI therapy.\n\nA total of approximately 46 male and female patients will be enrolled. This sample size is based on Simon's 2-stage design with historical control ORR of 30% and a target ORR of 50%.",[31,411],"Recurrent and\u002For Metastatic Head and Neck Squamous Cell Carcinoma",[31,413],"Recurrent and\u002For Metastatic Cancer","2026-01-21",{"date":416,"type":40},"2026-01-23",{"date":418,"type":40},"2022-09-30",{"date":420,"type":22},"2027-06-30",{"name":422,"class":125},"NATCO Pharma Ltd.",13,{"id":425,"slug":426,"hasResults":12,"nctId":427,"briefTitle":428,"officialTitle":429,"acronym":4,"eligibilityCriteria":430,"healthyVolunteers":12,"sex":69,"minAge":18,"maxAge":431,"enrollmentInfo":432,"targetDuration":434,"studyType":72,"phases":4,"briefSummary":435,"conditions":436,"keywords":448,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":459,"locationsCount":48},"100568077","vorolanib-in-the-second-line-treatment-of-patients-with-unresectable-or-metastatic-renal-cell-carcinoma-100568077","NCT06676527","Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma","An Observational Study of the Efficacy and Safety of Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma","Inclusion Criteria:\n\n* Subjects have fully understood and voluntarily signed the informed consent form (ICF);\n* 18-80 years old (at the time of signing the informed consent); Both men and women; ECOG PS score: 0-1;\n* Renal cell carcinoma with clear cell components confirmed histologically or cytopathologically, including unresectable or recurrent metastatic renal cell carcinoma dominated by clear cell components;\n* According to RECIST (version 1.1), there are targets that are considered to be observable;\n* The main organs function well.\n\nExclusion Criteria:\n\n* A history of malignancies other than the disease studied within the past 5 years, other than malignancies that are expected to be cured with treatment (including but not limited to adequately treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or breast ductal carcinoma in situ treated with radical surgery);\n* Systemic treatment with other antitumor agents, including targeted agents, immunotherapy agents and their combination regimens (eligible for inclusion after 5 half-lives), local antitumor therapy, or clinical investigational drug or device therapy within 4 weeks prior to the initial study;\n* Had major surgery within 4 weeks prior to initial study dosing (as judged by the investigator) or was in recovery;\n* A history of severe drug allergy, including but not limited to antibody drugs;\n* Patients with contraindications for immunotherapy restart;\n* A known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation may require long-term adrenal corticosteroid therapy. Patients with thyroid, suprarenal, or hypopituitarism that can be controlled by hormone replacement therapy alone, type 1 diabetes mellitus, and psoriasis or vitiligo that do not require systemic treatment are eligible to participate in this study;\n* Toxicity did not resolve after previous antitumor therapy, i.e., regression to baseline, NCI-CTCAE 5.0 level 0-1 (except for alopecia), or levels specified in inclusion\u002Fexclusion criteria. Irreversible toxicity (e.g., hearing loss) that is not reasonably expected to be aggravated by the drug under study may be included in the study;\n* Have central nervous system metastases and\u002For cancerous meningitis;\n* Known history of clinically significant liver disease, including those infected with viral hepatitis activity;\n* Patients with uncontrolled third space effusion requiring repeated drainage, such as pleural effusion, ascites, pericardial effusion, etc. (Patients with no need to drain effusion or no significant increase in effusion after 3 days of stopping drainage could be included);\n* Patients with any severe and\u002For uncontrolled disease;\n* Renal failure requires hemodialysis or peritoneal dialysis;\n* Have or have a suspected active autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, etc.;\n* History of live attenuated vaccine vaccination within 4 weeks prior to the initial study or expected live attenuated vaccine vaccination during the study period;\n* Those who have a history of psychotropic drug abuse and cannot abstain or have a history of mental disorders;\n* Other severe, acute, or chronic medical or psychiatric conditions or laboratory abnormalities, as determined by the investigator, that may increase the risks associated with study participation or that may interfere with the interpretation of the study results.","80 Years",{"count":433,"type":22},39,"12 Weeks","This is a multicenter real world study (RWS) initiated by the investigator. Eligible patients will be selected for treatment with second-line treatment including vorolanib and followed up. The real survival data of patients after medication will be collected and compared with the data of CONCEPT study, and multi-factor stratified analysis of the efficacy of voronib will be conducted.",[30,437,438,439,440,441,442,443,444,31,445,446,447],"Kidney Neoplasms","Urologic Neoplasms","Urogenital Neoplasms","Female Urogenital Diseases","Male Urogenital Diseases","Urogenital Diseases","Kidney Diseases","Urologic Diseases","Renal Cell Cancer","Carcinoma, Renal Cell","Antineoplastic Agents",[449,450,451],"observational study","clear cell Renal Cell Carcinoma","TKIs","2025-12-04",{"date":454,"type":40},"2025-12-05",{"date":456,"type":40},"2024-09-01",{"date":458,"type":22},"2026-09-01",{"name":460,"class":164},"Jinling Hospital, China",{"id":462,"slug":463,"hasResults":12,"nctId":464,"briefTitle":465,"officialTitle":465,"acronym":4,"eligibilityCriteria":466,"healthyVolunteers":12,"sex":69,"minAge":4,"maxAge":4,"enrollmentInfo":467,"targetDuration":469,"studyType":72,"phases":4,"briefSummary":470,"conditions":471,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":475,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":481,"locationsCount":48},"100509720","renal-cancer-monitoring-based-on-ctdna-methylomics-a-prospective-cohort-study-memory-study-100509720","NCT05917106","Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)","Inclusion Criteria:\n\n* Newly diagnosed renal cell carcinoma\n* Without any treatment\n* Agree and accept radical surgical treatment\n* Signed written informed consent\n* ECOG(Eastern Cooperative Oncology Group) performance is 0 or 1\n* Follow up protocol and related procedures\n\nExclusion Criteria:\n\n* Had other cancers\n* Had received any antitumor therapy before\n* Known or suspected active autoimmune disease\n* Informed consent is not possible due to medical or psychiatric problems\n* Have clinical symptoms or diseases of the heart that are not well controlled\n* Patients judged by the investigators to be unsuitable for inclusion in this study",{"count":468,"type":22},450,"5 Years","To conduct prospective studies to confirm the value of circulating tumor DNA and its abnormal methylation in longitudinal monitoring of patients undergoing kidney cancer surgery.",[31,472,473,437,474],"Renal Cell Carcinoma","RCC","Kidney Cancer",{"date":476,"type":40},"2025-12-11",{"date":478,"type":40},"2022-12-26",{"date":480,"type":22},"2030-06",{"name":460,"class":164},{"id":483,"slug":484,"hasResults":12,"nctId":485,"briefTitle":486,"officialTitle":486,"acronym":4,"eligibilityCriteria":487,"healthyVolunteers":12,"sex":69,"minAge":488,"maxAge":4,"enrollmentInfo":489,"targetDuration":4,"studyType":23,"phases":490,"briefSummary":491,"conditions":492,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":48},"100612341","a-single-arm-phase-ii-clinical-study-investigating-the-safety-and-efficacy-of-carbon-ion-radiotherapy-in-patients-with-hepatocellular-carcinoma-previously-treated-with-transarterial-radioembolization-tare-100612341","NCT07252323","A Single-arm Phase II Clinical Study Investigating the Safety and Efficacy of Carbon Ion Radiotherapy in Patients With Hepatocellular Carcinoma Previously Treated With Transarterial Radioembolization (TARE)","Inclusion Criteria:\n\n* adult patients over the age of 19 Hepatocellular carcinoma patients confirmed imagingly or histologically Patients who have a residual lesion in the TARE-treated area or have a recurrence or progressive lesion in the TARE-treated area or nearby liver and are deemed to need additional treatment when evaluating the response for more than 6 months Child-Pugh Class A (Child-Pugh score 5-6), B (CP score 7) Patients who fall within the range of lesions that can afford the baryon treatment intended in this study Patients who have minimal availability of liver excluded from treatment in terms of preservation of liver function proper liver function Patients with AST\u002FALT less than 5 times the upper limit of normal If you don't have blood clotting disorder ECOG performance status 2 or lower Patients who are not pregnant or who are undergoing appropriate contraception for women of childbearing age No other underlying conditions that seriously affect survival Patients who have listened to and agreed to a documented explanation and a statement of consent\n\nExclusion Criteria:\n\n* If you've had external radiotherapy in your liver Patients with unresolved infections at that point Patients who have a current or other history of advanced carcinoma within 5 years a patient who underwent a liver transplant If baryon treatment is inappropriate or dangerous under the judgment of a radiologic oncologist","20 Years",{"count":135,"type":22},[176],"This is a prospective, single-arm Phase II study designed to evaluate the safety and efficacy of carbon ion radiotherapy in patients with hepatocellular carcinoma (HCC) who demonstrate residual or recurrent disease after prior transarterial radioembolization (TARE). Carbon ion radiotherapy delivers highly conformal, high-linear energy transfer radiation, enabling dose escalation to hepatic tumors while minimizing exposure to surrounding normal tissues.\n\nEligible patients will receive carbon ion radiotherapy to target lesions, and clinical outcomes including objective response rate, progression-free survival, overall survival, and treatment-related toxicity will be systematically assessed. The study aims to determine whether carbon ion radiotherapy can provide effective local tumor control and acceptable safety in this population, thereby establishing evidence to guide its therapeutic role following TARE.",[31,493],"Hepatocellular Carcinoma","2025-11-18",{"date":496,"type":40},"2025-11-26",{"date":498,"type":40},"2024-11-12",{"date":500,"type":22},"2026-11",{"name":502,"class":164},"Yonsei University",{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":507,"acronym":4,"eligibilityCriteria":508,"healthyVolunteers":12,"sex":69,"minAge":488,"maxAge":4,"enrollmentInfo":509,"targetDuration":4,"studyType":23,"phases":510,"briefSummary":511,"conditions":512,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":516,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":522,"locationsCount":48},"100611906","phase-2-a-phase-ii-single-arm-clinical-study-to-evaluate-the-efficacy-and-safety-of-carbon-ion-radiotherapy-with-atezolizumab-and-bevacizumab-combination-therapy-in-patients-with-advanced-hepatocellular-carcinoma-100611906","NCT07246668","A Phase II Single-Arm Clinical Study to Evaluate the Efficacy and Safety of Carbon Ion Radiotherapy With Atezolizumab and Bevacizumab Combination Therapy in Patients With Advanced Hepatocellular Carcinoma","Inclusion Criteria:\n\n* Age ≥ 18 years Histologically or radiologically confirmed hepatocellular carcinoma (HCC) Barcelona Clinic Liver Cancer (BCLC) stage B or C, not eligible for curative surgery or transplantation.\n\nAt least one measurable lesion according to RECIST criteria. Eligible for treatment with atezolizumab plus bevacizumab based on clinical judgment.\n\nCandidate for carbon ion radiotherapy determined by radiation oncologist. Child-Pugh class A liver function Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n\nAdequate organ and marrow function, including:\n\nAbsolute neutrophil count ≥ 1,500\u002FμL Platelet count ≥ 75,000\u002FμL Hemoglobin ≥ 8.5 g\u002FdL Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 50 mL\u002Fmin AST\u002FALT ≤ 5 × ULN Total bilirubin ≤ 3 mg\u002FdL No uncontrolled esophageal or gastric varices, confirmed by endoscopy (within 6 months), or adequately treated before enrollment.\n\nAbility to understand and willingness to sign a written informed consent form.\n\nExclusion Criteria:\n\n* Prior systemic therapy with anti-PD-1, anti-PD-L1, or anti-VEGF agents within the past year.\n\nPrior carbon ion radiotherapy to the same anatomical region.\n\nPresence of uncontrolled or severe cardiovascular disease, including:\n\nRecent myocardial infarction (within 6 months) Uncontrolled hypertension NYHA class III-IV heart failure Active or history of autoimmune disease requiring systemic immunosuppressive therapy.\n\nActive infection, including:\n\nUncontrolled bacterial, viral, or fungal infection Active tuberculosis HIV infection, or active hepatitis B\u002FC with uncontrolled viral replication.\n\nSignificant bleeding risk, including:\n\nActive gastrointestinal bleeding Untreated or high-risk varices Coagulopathy not controllable with standard therapy Portal vein tumor thrombosis (PVTT) of grade Vp4 if judged unsuitable for treatment by investigator.\n\nPregnant or breastfeeding women History of organ transplantation, including liver transplantation. Any condition judged by the investigator to interfere with study participation, treatment compliance, or safety evaluation.",{"count":21,"type":22},[25],"This single-center, prospective phase II clinical trial evaluates the safety and therapeutic efficacy of combining carbon ion radiotherapy with the standard first-line regimen of atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma. The study aims to determine whether the addition of carbon ion radiotherapy enhances tumor control and improves clinical outcomes beyond those achieved with systemic therapy alone. Key endpoints include overall survival, progression-free survival, objective response rate, and treatment-related adverse events.",[493,513,31,514],"Liver Neoplasms","Hepatocellular","2025-11-17",{"date":517,"type":40},"2025-11-24",{"date":519,"type":40},"2025-03-10",{"date":521,"type":22},"2028-03",{"name":502,"class":164},{"id":524,"slug":525,"hasResults":12,"nctId":526,"briefTitle":527,"officialTitle":527,"acronym":4,"eligibilityCriteria":528,"healthyVolunteers":12,"sex":69,"minAge":4,"maxAge":4,"enrollmentInfo":529,"targetDuration":531,"studyType":72,"phases":4,"briefSummary":532,"conditions":533,"keywords":571,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":590,"completionDateStruct":592,"leadSponsor":594,"locationsCount":596},"100320510","synergy-ai-artificial-intelligence-based-precision-oncology-clinical-trial-matching-and-registry-100320510","NCT03452774","SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","Inclusion Criteria:\n\n* Pts with solid and hematological malignancies;\n* Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2, HER2\u002FNeu, Tumor mutational burden\u002Fload (TMB), ABL1, ACVR1B, AKT1, AKT2, AKT3, ALK, APC, AR, ATM, ATRX, AURKA, AURKB, BAP1, BCL2, BCL6, BRAF, BRCA1, BRCA2, BTK, CCND1, CCND2, CCND3, CDK4, CDK6, CDKN1A\u002FB, CEBPA, CHEK1, CHEK2, CSF1R, CTNNB1, DAXX, DDR1\u002F2, DNMT3A, EGFR, ERBB2, ERBB3, ERBB4, ERCC4, ER, ESR1, FANCA, FAS, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GATA3, GATA6, GNAS, HDAC1, HGF, HRAS, IDH1, IDH2, IGF1R, JAK1, JAK2, JAK3, KDR (VEGFR2), KIT, KRAS, MAP2K2 (MEK2), MAP3K1, MCL1, MDM2, MDM4, MEN1, MET, MSH2, MSH3, MSH6, MTOR, MUTYH, MYC, MYCL (MYCL1), NF1, NF2, NOTCH1, NPM1, NRAS, NTRK1, NTRK2, NTRK3, PALB2, PARP1, PARP2, PARP3, PBRM1, PDCD1 (PD1), PDCD1LG2 (PD-L2), PDGFRA, PDGFRB, PIK3C, PMS2, POLD1, POLE, PRDM1, PTCH1, PTEN, RAF1, RB1, RET, RICTOR, ROS1, RPTOR, SDHA\u002FB\u002FC, SMAD, SMARC, SMO, STK11, TGFBR2, TP53, TSC1, TSC2, VEGFA, VHL, WT1, ZNF217, ZNF703, CEACAM, NRG1, among others.\n\nThese biomarkers should be determined by local laboratory, external vendor, or next generation sequencing platform\n\n* Decision to consider clinical trial pre-screening enrollment (CTE) by primary provider and\u002For patient\n\nExclusion Criteria:\n\n* ECOG PS \\> 2;\n* Abnormal organ function;\n* Hospice enrollment",{"count":530,"type":22},50000,"36 Months","International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.",[534,329,535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,551,31,552,553,554,555,556,557,236,558,152,559,560,378,273,561,562,563,564,565,566,567,568,569,570],"Cancer, Metastatic","Cancer of Pancreas","Cancer of Liver","Cancer of Stomach","Cancer Liver","Cancer of Rectum","Cancer of Kidney","Cancer of Esophagus","Cancer of Cervix","Cancer of Colon","Cancer of Larynx","Cancer, Lung","Cancer, Breast","Cancer, Advanced","Cancer Prostate","Cancer of Neck","Cancer of Skin","Neuroendocrine Tumors","Mismatch Repair Deficiency","BRCA Gene Rearrangement","Non Hodgkin Lymphoma","Leukemia","Non Small Cell Lung Cancer","Cholangiocarcinoma","Central Nervous System Tumor","Urothelial Carcinoma","Bladder Cancer","Testicular Cancer","Breast Cancer","COVID","Myelofibrosis","Myeloproliferative Neoplasm","Myeloproliferative Disorders","Follicular Lymphoma","Mantle Cell Lymphoma","Marginal Zone Lymphoma","Myelodysplastic Syndromes",[572,573,574,575,576,577,578,579,580,581,582,583,584,585,586],"artificial intelligence","virtual tumor board","clinical trial","clinical trial matching","electronic medical record","machine learning","cost of care","targeted therapy","immunotherapy","precision medicine","precision oncology","cancer","value based care","real world data","data analytics","2025-10-25",{"date":589,"type":40},"2025-10-28",{"date":591,"type":40},"2018-01-01",{"date":593,"type":22},"2040-06",{"name":595,"class":125},"Massive Bio, Inc.",68,{"id":598,"slug":599,"hasResults":12,"nctId":600,"briefTitle":601,"officialTitle":602,"acronym":4,"eligibilityCriteria":603,"healthyVolunteers":12,"sex":69,"minAge":18,"maxAge":431,"enrollmentInfo":604,"targetDuration":606,"studyType":72,"phases":4,"briefSummary":607,"conditions":608,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":609,"lastUpdatePostDateStruct":610,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":616,"locationsCount":618},"100606815","the-treatment-of-unresectable-liver-cancer-with-e-tace-combined-with-donafeniba-prospective-single-arm-multicenter-observational-study-100606815","NCT07180459","The Treatment of Unresectable Liver Cancer With E-TACE Combined With Donafenib：A Prospective, Single-arm, Multicenter, Observational Study","The Treatment of Unresectable Liver Cancer With Graded Embolization of Uniform-sized Drug-loaded Microspheres Combined With Donafenib：A Prospective, Single-arm, Multicenter, Observational Study","Inclusion Criteria:\n\n* (1) Patients with unresectable primary liver cancer who strictly meet the clinical diagnostic criteria of the \"Primary Liver Cancer Diagnosis and Treatment Guidelines\" (2024 Edition) or who have been diagnosed through pathological histology or cytology examination, and who have at least one measurable lesion (according to the mRECIST 1.1 version, the long diameter of the measurable lesion on spiral CT scan should be ≥ 10mm or the short diameter of the enlarged lymph node should be ≥ 15mm); (2) Tumor staging: CNLC stage Ib, IIa, IIb, IIIa, IIIb or BCLC A, B, C stage; non-diffuse liver cancer (PVTT classified according to the Japanese Liver Cancer Research Society's portal vein tumor thrombus characteristics as Vp1\u002F2, Vp3, Vp4); (3) Gender of the patients is not restricted, and the age is 18-80 years old; expected lifespan is ≥ 3 months; (4) Within 1 week before enrollment, the ECOG PS score: 0-1; (5) No severe comorbidities, such as hypertension, coronary heart disease and history of mental illness, no severe allergy history; (6) Liver function should reach Child-Pugh grade A or B; (7) Laboratory tests meet the following requirements: platelets ≥ 50×109\u002FL; hemoglobin ≥ 9g\u002FdL; white blood cells ≥ 4×109\u002FL; neutrophils ≥ 1.5×109\u002FL); serum total bilirubin ≤ 1.5 times the upper limit of normal value (ULN), transaminases (ALT, AST) ≤ 5 times ULN; creatinine ≤ 1.5 times ULN; urine routine shows urine protein \\\u003C 2+; for patients whose urine protein ≥ 2+ at baseline, 24-hour urine collection should be conducted and the 24-hour urine protein quantification \\\u003C 1g; international normalized ratio (INR) or activated partial thromboplastin time (APTT) ≤ 1.5 times ULN; (8) HBV DNA \\\u003C 2000 IU\u002Fml (104 copies\u002Fml); (9) For pregnant women of childbearing age, a pregnancy test should be conducted within 7 days before enrollment; (10) Patients have signed the informed consent form agreeing to participate in this trial study; good compliance and cooperation with treatment.\n\nExclusion Criteria:\n\n* (1) Imaging examination shows that the liver tumor is huge (≥ 60% of liver volume), or there is a main portal vein tumor thrombus (occupying the vascular diameter ≥ 50%), or the tumor thrombus invades the mesenteric vein or inferior vena cava, or there are obvious native hepatic artery - portal vein fistulas and native hepatic artery - hepatic vein fistulas that cannot safely use drug-loaded microspheres; (2) Before participating in this study, they have undergone local treatments such as traditional TACE, thermal ablation, cryoablation, external radiotherapy and radioactive particle implantation, and have received systemic chemotherapy, oral liver cancer targeted drugs (sorafenib, lenafolate, apatinib) and immune therapy (PD-1\u002FPD-L1\u002FCDLA-4\u002Fbiologic double therapy); (3) Patients with diffuse liver cancer; known hepatocellular carcinoma and mixed cell carcinoma and fibroplastic cell carcinoma; having other untreated malignant tumors in the past (within 5 years) or simultaneously; except for cured skin basal cell carcinoma and cervical carcinoma in situ; (4) Having grade II or above myocardial ischemia or myocardial infarction, and uncontrolled arrhythmia (including QTc interval for males ≥ 450ms, females ≥ 470ms); (5) Having a history of gastrointestinal bleeding in the past 6 months or having a clear tendency for gastrointestinal bleeding, such as: esophageal varices with bleeding risk, local active ulcer lesion, fecal occult blood ≥ (++), not eligible for inclusion; if fecal occult blood (+), a gastroscopy examination is required; (6) Abnormal coagulation function (INR \\> 1.5 or prothrombin time (PT) \\> ULN + 4 seconds), bleeding tendency or undergoing thrombolysis or anticoagulation treatment; (7) Patients with central nervous system metastasis or known brain metastasis; having objective evidence of past and current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, severe impairment of pulmonary function; patients with combined HIV infection; pregnant or lactating patients; patients preparing for liver transplantation (except for patients who have undergone liver transplantation in the past); (8) Severe systemic failure, with an expected survival period \\\u003C 3 months; (9) Severe renal dysfunction (creatinine \\> 2mg\u002Fdl or creatinine clearance rate \\\u003C 30ml\u002Fmin); (10) Unable to complete the treatment plan due to various reasons, and lost follow-up within three months after enrollment.",{"count":605,"type":22},118,"1 Year","To clarify the safety and efficacy of using uniform-sized drug-loaded embolic microspheres (E-TACE) of different particle sizes for graded embolization during TACE combined with Donafenib in the treatment of unresectable primary liver cancer. To determine whether this therapy can prolong the ORR, DCR, PFS, OS and other indicators.",[31,493],"2025-09-12",{"date":611,"type":40},"2025-09-18",{"date":613,"type":22},"2025-10-10",{"date":615,"type":22},"2027-10-10",{"name":617,"class":164},"Xuhua Duan",10,{"id":620,"slug":621,"hasResults":12,"nctId":622,"briefTitle":623,"officialTitle":624,"acronym":625,"eligibilityCriteria":626,"healthyVolunteers":12,"sex":69,"minAge":18,"maxAge":4,"enrollmentInfo":627,"targetDuration":4,"studyType":23,"phases":629,"briefSummary":630,"conditions":631,"keywords":641,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":666,"lastUpdatePostDateStruct":667,"startDateStruct":669,"completionDateStruct":671,"leadSponsor":673,"locationsCount":675},"100484789","phase-1-a-study-of-a-selective-t-cell-receptor-tcr-targeting-bifunctional-antibody-fusion-molecule-star0602-in-participants-with-advanced-solid-tumors-100484789","NCT05592626","A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors","A Phase 1\u002F2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects With Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)","START-001","Inclusion Criteria:\n\n1. Participants must have histologically confirmed solid tumors that are unresectable, locally advanced, or metastatic and for which standard curative therapies do not exist or are no longer effective or have intolerable toxicities. Subjects should not have received more than three lines of prior therapies for their advanced or metastatic diseases.\n2. For Phase 1, participants must have one of the following solid tumors:\n\n   1. High mutational burden (TMB-H)\n   2. Microsatellite Instability (MSI-H)\u002FDNA mismatch repair (dMMR)\n   3. Virally associated tumors\n3. For Phase 2, participants must have one of the following solid tumors:\n\n   1. TMB-H\n   2. MSI-H\u002FdMMR\n   3. CRC (both Ras wild type and mutant)\n   4. Virally associated tumors\n   5. Metastatic triple negative breast cancer\n   6. Platinum-resistant epithelial ovarian cancer\n   7. Metastatic castration-resistance prostate cancer\n   8. Primary stage IV or recurrent non-small cell lung cancer\n   9. Immunogenic solid tumors\n\n   (Other tumor histologies may also be included in Phase 2 as additional data emerge to support their inclusion.)\n4. Symptomatic central nervous system (CNS) metastases must have been treated, be asymptomatic for ≥ 14 days, and meet the following at the time of enrollment:\n\n   * No concurrent treatment for CNS disease (e.g., surgery, radiation, corticosteroids \\> 10 mg prednisone\u002Fday or equivalent);\n   * No concurrent leptomeningeal disease or cord compression.\n\nExclusion Criteria:\n\n1. Participants with a history of known autoimmune disease with exceptions of:\n\n   * Vitiligo;\n   * Psoriasis, atopic dermatitis or other autoimmune skin condition not requiring systemic treatment;\n   * History of Graves' disease, now euthyroid for \\> 4 weeks;\n   * Hypothyroidism managed by thyroid replacement;\n   * Alopecia;\n   * Arthritis managed without systemic therapy beyond oral nonsteroidal anti-inflammatory drugs.\n   * Adrenal insufficiency well controlled on replacement therapy.\n2. Major surgery or traumatic injury within 8 weeks before first dose of study drug.\n3. Unhealed wounds from surgery or injury.\n4. Treatment with \\>10 mg per day of prednisone (or equivalent) or other immune-suppressive drugs within 7 days prior to the initiation of study drug. Exceptions may be made for patients who have had allergic reaction to iodinated contrast media. Steroids for topical, ophthalmic, inhaled, or nasal administration are allowed.\n5. Clinically significant cardiovascular\u002Fvascular disease, gastrointestinal disorders, inflammatory processes, pulmonary compromises\n6. Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days prior to the initiation of study drug.\n7. Vaccination with any live virus vaccine within 4 weeks prior to the initiation of study drug administration. Inactivated annual influenza vaccination is allowed.\n8. Participants who are known to be human immunodeficiency virus positive or hepatitis B or C positive and have uncontrolled disease.\n9. Second primary invasive malignancy not in remission for ≥ 1 year. Exceptions include non-melanoma locally advanced skin cancer, cervical carcinoma in situ, localized prostate cancer (Gleason score ≤ 7), resected melanoma in situ, or any malignancy considered to be indolent and never required systemic therapy, with the exception of indolent lymphomas.\n10. Pregnant, likely to become pregnant, or lactating women (where pregnancy is defined as the state of a female after conception and until the termination of gestation).\n11. Hepatic metastases unless adequately treated, either locally (e.g., by surgery, radiofrequency ablation, or chemoembolization) or systemically or both, and stable for 3 months.",{"count":628,"type":22},365,[137,25],"This is an open label, multicenter, phase 1\u002F2 study to assess the safety\u002Ftolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-rich.",[632,633,439,634,635,636,637,31,30,638,639,640],"Advanced Solid Tumors","Genital Neoplasm, Female","Lung Neoplasm","Neoplasms by Site","Papillomavirus Infection","Epstein-Barr Virus Infections","Vulvar Neoplasms","Vulvar Diseases","Abdominal Neoplasm",[632,642,643,447,644,645,646,647,648,649,650,651,652,653,654,655,656,657,152,658,659,660,273,661,662,663,664,244,665,560],"STAR0602","Intravenous","T Cell Receptor-targeting","Bifunctional Antibody-Fusion","Specific T Cell Activator","Tumor Mutational Burden (TMB) High","Microsatellite Instability (MSI) High","Virally Associated Malignancies","Checkpoint Inhibitor Resistance","Immunotherapy","Immune Checkpoint Inhibitor Resistance","Head and Neck Cancer","Nasopharyngeal Cancer","Non-small Cell Lung Cancer","Small Cell Lung Cancer","Biliary Cancer","Merkel Cell Carcinoma","Skin Squamous Cell Carcinoma","Skin Basal Cell Carcinoma","Colorectal Cancer","Small Bowel Cancer","Cervical Cancer","Gastrointestinal Neoplasms","Esophageal Cancer","2025-07-07",{"date":668,"type":40},"2025-07-09",{"date":670,"type":40},"2023-01-04",{"date":672,"type":22},"2026-10",{"name":674,"class":125},"Marengo Therapeutics, Inc.",32,{"id":677,"slug":678,"hasResults":12,"nctId":679,"briefTitle":680,"officialTitle":681,"acronym":4,"eligibilityCriteria":682,"healthyVolunteers":12,"sex":69,"minAge":18,"maxAge":683,"enrollmentInfo":684,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":686,"conditions":687,"keywords":688,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":693,"lastUpdatePostDateStruct":694,"startDateStruct":696,"completionDateStruct":698,"leadSponsor":699,"locationsCount":48},"100543619","predicting-non-small-cell-lung-cancer-nsclc-lymph-node-metastasis-integrating-circulating-tumor-dna-ctdna-mutation-methylation-profiling-with-positron-emission-tomography-computed-tomography-pet-ct-scan-100543619","NCT06358222","Predicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) Mutation\u002F Methylation Profiling With Positron Emission Tomography-computed Tomography (PET-CT) Scan","Predicting NSCLC Lymph Node Metastasis: Integrating ctDNA Mutation\u002F Methylation Profiling With PET-CT Scan: The LUNon-invasive Study","Inclusion Criteria:\n\n1. Provision of informed consent prior to study initiation.\n2. Age between 18 and 75 years.\n3. Preoperative clinical evaluation indicating non-small cell lung cancer (NSCLC) stage I-IIIB (without initial treatment sought).\n4. Newly treated patients who have consented to undergo surgery.\n5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-1.\n\nExclusion Criteria:\n\n1. Non-small cell lung cancer (NSCLC) histopathologically determined to be other than stage I-IIIB following surgical evaluation.\n2. Presence of other active malignant tumor diseases.\n3. Evidence of any serious or uncontrolled systemic illness, including uncontrolled hypertension and active bleeding, as assessed by the investigator, which may contribute to reluctance to participate in the trial or decrease adherence to the study regimen. Additionally, active infectious diseases such as hepatitis B, hepatitis C, and human immunodeficiency virus (HIV) infection are grounds for exclusion.\n4. History of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis requiring steroid therapy, or any indication of clinically active ILD.\n5. Patients considered by the investigator to be unable to comply with the study protocol, restrictions, and requirements, or those facing circumstances at the investigator's discretion that would impede their participation in the study.","75 Years",{"count":685,"type":22},200,"This is a single center, prospective and observational study conducted in three stages to predict the NSCLC lymph node metastasis based on ctDNA\u002Fspecific methylation molecular features combined with PET-CT imaging features and intervention study.",[31,655],[655,689,690,691,692],"ctDNA","PET-CT","methylation","lymph node metastasis","2025-05-14",{"date":695,"type":40},"2025-05-18",{"date":697,"type":40},"2023-12-15",{"date":81,"type":22},{"name":700,"class":164},"Shanghai Chest Hospital",{"id":702,"slug":703,"hasResults":12,"nctId":704,"briefTitle":705,"officialTitle":706,"acronym":4,"eligibilityCriteria":707,"healthyVolunteers":12,"sex":69,"minAge":606,"maxAge":18,"enrollmentInfo":708,"targetDuration":4,"studyType":23,"phases":710,"briefSummary":711,"conditions":712,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":715,"startDateStruct":717,"completionDateStruct":718,"leadSponsor":720,"locationsCount":48},"100590601","phase-2-safety-and-efficacy-of-pucotenlimab-in-plecc-100590601","NCT06969534","Safety and Efficacy of Pucotenlimab in pLECC","Phase II Clinical Study on the Safety and Efficacy of Pucotenlimab Combined With the Chemotherapy Regimen of Gemcitabine and Cisplatin for Lymphoepithelioma-like Carcinoma in Children and Adolescents","Inclusion Criteria:\n\n* Age: Between 1 and 18 years old;\n* ECOG PS score: 0 to 1 point;\n* Histopathologically confirmed locally advanced or metastatic lymphoepithelioma-like carcinoma in children or adolescents;\n* Must have at least one measurable lesion defined by the RECIST or WHO criteria;\n* Estimated survival time ≥ 6 months;\n* Cardiac function:Left ventricular ejection fraction (LVEF) detected by echocardiography ≥ 50%; Electrocardiogram (EKG) shows no signs of myocardial ischemia;\n* No history of arrhythmia requiring drug intervention before enrollment;\n* No history of severe immune-related adverse events (CTCAE V4.03 Grade 3 or Grade 4);\n* For patients known not to have bone marrow (BM) involvement:Absolute neutrophil count (ANC) ≥ 1.0×10⁹\u002FL; Platelet count ≥ 100.0×10⁹\u002FL;Hemoglobin ≥ 90 g\u002FL;\n* Liver and kidney functions should meet the following criteria: Total bilirubin (conjugated + unconjugated) ≤ 2.5× the upper limit of normal value (ULN) (corresponding to the age). Patients with confirmed Gilbert's syndrome can be considered for enrollment at the discretion of the investigator;Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5× ULN; Estimated glomerular filtration rate ≥ 30 mL\u002Fmin\u002F1.73 m² or serum creatinine (Cr) ≤ 1.5× ULN;\n* During participation in the study, be able to comply with outpatient treatment, laboratory monitoring and necessary clinical visits;\n* The parents\u002Fguardians of child or adolescent subjects are capable of understanding, consenting to and signing the Informed Consent Form (ICF) for the study and the applicable child consent form before any protocol-related procedures are initiated. With the consent of the parents\u002Fguardians, the subject is capable of expressing consent (when applicable).\n\nExclusion Criteria:\n\n* Have received anti-PD-1 or anti-PD-L1 monoclonal antibodies or targeted drugs of related pathways;\n* Known to be allergic to PD-1 monoclonal antibody or any of its excipients; Known to have a history of allergic diseases or have a severe allergic constitution;\n* Have other malignant tumor diseases other than the tumor being treated in this study, except for: Malignant tumors that have been cured and have not recurred within 3 years before study enrollment, completely resected basal cell and squamous cell skin cancers, and any type of in-situ cancer that has been completely resected;\n* Active central nervous system metastases (whether treated or not), including symptomatic brain metastases, meningeal metastases, spinal cord compression, etc.; Except for: Asymptomatic brain metastases (no progression within at least 4 weeks after radiotherapy and\u002For no neurological symptoms or signs after surgical resection, and no need for dexamethasone or mannitol treatment).\n* Uncontrollable pleural effusion, pericardial effusion or ascites that requires repeated drainage;\n* The toxicity of previous treatment is still \\> Grade 1 (CTCAE V4.03 criteria), except for alopecia and neurotoxicity;\n* Have a history of mental disorders;\n* Have a history of drug abuse or drug addiction as determined by inquiry;\n* Have a history of idiopathic pulmonary fibrosis or idiopathic pneumonia;\n* Have comorbidities that require treatment with immunosuppressive drugs, or have comorbidities that require systemic or local use of corticosteroids at immunosuppressive doses (prednisone \\> 10 mg\u002Fday or equivalent dose of similar drugs).\n* Have a history of autoimmune diseases, including but not limited to systemic lupus erythematosus, psoriasis, rheumatoid arthritis, inflammatory bowel disease, Hashimoto's thyroiditis, etc., except for: Type 1 diabetes mellitus, hypothyroidism that can be controlled only by hormone replacement therapy, skin diseases that do not require systemic treatment (such as vitiligo, psoriasis), celiac disease that has been controlled, or diseases that are not expected to recur without external stimulating factors;\n* Have a history of previous or current active tuberculosis infection;\n* Have active infections that require systemic treatment;\n* Uncontrolled hypertension (systolic blood pressure ≥ 140 mmHg and\u002For diastolic blood pressure ≥ 90 mmHg), or pulmonary hypertension, or unstable angina pectoris; Have had a myocardial infarction or undergone coronary artery bypass grafting or stenting surgery within 6 months before drug administration; Have a history of chronic heart failure meeting New York Heart Association (NYHA) criteria Class 3-4; Have clinically significant valvular heart disease; Have severe arrhythmias that require treatment (excluding atrial fibrillation and paroxysmal supraventricular tachycardia), including a QTc interval of ≥ 450 ms for men and ≥ 470 ms for women (calculated by the Fridericia formula); Have had a cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 6 months before drug administration, etc.;\n* Have severe medical comorbidities, including but not limited to: Uncontrolled diabetes mellitus, active peptic ulcer, active bleeding, etc.;\n* Positive for Anti-HIV, TP-Ab, HCV-Ab; Positive for HBV-Ag and the HBV DNA copy number \\> the upper limit of the normal value of the testing unit;\n* Abnormal thyroid function test results (FT3, FT4, T3, T4);\n* Expected to receive live vaccines or attenuated vaccines within 4 weeks before drug administration, during the treatment period, or within 5 months after the last drug administration;\n* Have participated in another clinical trial and received the investigational drug treatment within 30 days before drug administration;\n* Patients who, according to the judgment of the investigator, are not suitable for participating in this trial for other reasons.",{"count":709,"type":22},33,[25],"Lymphoepithelioma-like carcinoma (LELC) in children is a rare epithelial malignant tumor. Regarding pediatric lymphoepithelioma-like carcinoma (pLELC), its clinicopathological features, prognosis, and molecular characteristics remain unknown. In preclinical studies, this study aims to explore the safety and efficacy of the PD-1 monoclonal antibody pucotenlimab combined with the chemotherapy regimen of gemcitabine and cisplatin as the first-line treatment for lymphoepithelioma-like carcinoma in children and adolescents.",[713,714,31],"Lymphoepithelioma-like Carcinoma","Lymphoepithelioma",{"date":716,"type":40},"2025-05-15",{"date":716,"type":22},{"date":719,"type":22},"2028-12-30",{"name":721,"class":164},"Sun Yat-sen University",{"id":723,"slug":724,"hasResults":12,"nctId":725,"briefTitle":726,"officialTitle":727,"acronym":4,"eligibilityCriteria":728,"healthyVolunteers":12,"sex":69,"minAge":4,"maxAge":4,"enrollmentInfo":729,"targetDuration":375,"studyType":72,"phases":4,"briefSummary":731,"conditions":732,"keywords":743,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":749,"lastUpdatePostDateStruct":750,"startDateStruct":752,"completionDateStruct":754,"leadSponsor":756,"locationsCount":364},"100474888","oral-hedgehog-inhibitors-in-the-treatment-of-basal-cell-carcinoma-in-the-netherlands-a-prospective-registration-study-100474888","NCT05463757","Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study","Registration of Oral Hedgehog Inhibitors Vismodegib and Sonidegib in the Treatment of Advanced and Multiple Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study.","Inclusion Criteria:\n\n* Men and women\n* All ages\n* Diagnosed with locally advanced basal cell carcinoma (laBCC), metastatic basal cell carcinoma (mBCC), multiple basal cell carcinomas or Gorlin syndrome\n* Use of oral hedgehog inhibitor vismodegib or sonidegib\n\nExclusion Criteria:\n\n* None",{"count":730,"type":22},80,"Background: Oral hedgehog inhibitors vismodegib and sonidegib have been used for the treatment of locally advanced (laBCC), metastatic basal cell carcinoma (mBCC) and in basal cell nevus syndrome (BCNS) patients. In the Netherlands, targeted therapy with vismodegib and sonidegib has been available since 2013 and 2021, respectively. No direct comparative studies have been performed between the two oral hedgehog inhibitors (HHI) vismodegib and sonidegib yet . In addition, data for sonidegib are not yet available.\n\nObjective: The aim of this study is 1) to evaluate the effectiveness of oral HHIs in the treatment of laBCC, mBCC and BCNS patients and 2) to compare the oral HHIs vismodegib and sonidegib.\n\nStudy design: prospective registration study that includes all patients, regardless of age and gender, with histologically proven basal cell carcinoma receiving treatment with either vismodegib or sonidegib in the Netherlands. Patient, tumor and treatment information was gathered from patient records.\n\nMain study parameters\u002Fendpoints: The primary outcome for measuring efficacy\u002Ftumor response was median progression free survival (PFS) where the decrease, stagnation or increase in tumor size is measured by maximum diameter. Secondary outcomes are frequency, severity and reversibility of treatment-emergent adverse events and disease-specific quality of life expressed as mean scores on the EORTC-QLQ-C30 and aBCCdex questionnaires.",[733,734,735,736,737,738,31,739,740,741,742],"Basal Cell Carcinoma","Locally Advanced Basal Cell Carcinoma","Metastatic Basal Cell Carcinoma","Gorlin Syndrome","Basal Cell Nevus Syndrome","Carcinoma, Basal Cell","Basal Cell Tumor","Skin Cancer","Neoplasm of Skin","Neoplasms, Basal Cell",[744,745,746,747,748],"Oral hedgehog inhibitors","Vismodegib","Sonidegib","Erivedge","Odomzo","2025-04-02",{"date":751,"type":40},"2025-04-04",{"date":753,"type":40},"2021-11-01",{"date":755,"type":22},"2026-12",{"name":757,"class":164},"Maastricht University Medical Center",{"id":759,"slug":760,"hasResults":12,"nctId":761,"briefTitle":762,"officialTitle":763,"acronym":4,"eligibilityCriteria":764,"healthyVolunteers":12,"sex":69,"minAge":18,"maxAge":4,"enrollmentInfo":765,"targetDuration":4,"studyType":23,"phases":767,"briefSummary":768,"conditions":769,"keywords":771,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":774,"lastUpdatePostDateStruct":775,"startDateStruct":777,"completionDateStruct":779,"leadSponsor":781,"locationsCount":48},"100340108","phase-2-preoperative-immunotherapy-in-patients-with-squamous-cell-carcinoma-of-the-head-and-neck-100340108","NCT03708224","Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck","A Phase II Study of Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck","Inclusion Criteria:\n\n1. Patients must have clinically suspected SCCHN that is amenable to surgical resection with therapeutic intent\n2. Be willing and able to provide written informed consent\u002Fassent for the trial\n3. Be \\>=18 years of age on day of signing informed consent.\n4. Agree to research analysis of an existing pre-treatment biopsy available that was obtained within 90 days prior to the day of consent or agree to a new biopsy for research (or clinical diagnosis) within the screening window. Needle biopsies must be at least 20 Gauge in diameter\n5. Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) performance scale\n6. Demonstrate adequate organ function as defined below. All screening labs should be performed within 14 days of treatment initiation\n\n   * Absolute neutrophil count (ANC) \\>=1,500 \u002Fmicroliter (mcL)\n   * Platelets \\>=100,000 \u002F mcL\n   * Hemoglobin \\>= 9 g\u002FdL\n   * Lymphocyte count \\>= 500\u002FmcL\n   * White blood count \\>=3,000\u002FmcL or \\\u003C=14,000\u002FmcL\n   * Serum creatinine =\\\u003C 1.5 x upper limit of normal (ULN) OR ≥50 mL\u002Fmin creatinine clearance by Cockcroft-Gault formula for participants in whom, in the Investigator's judgment, serum creatinine levels do not adequately reflect renal function. \\* Creatinine clearance should be calculated per institutional standard\n   * Serum total bilirubin =\\\u003C 1.5 x ULN OR direct bilirubin =\\\u003C ULN for subjects with total bilirubin levels \\> 1.5 ULN\n\n     \\* Excluding Gilbert's syndrome. Participants with Gilbert's syndrome will be eligible for the study. The diagnosis of Gilbert's syndrome is suspected in people who have persistent, slightly elevated levels of unconjugated bilirubin (\\\u003C= 3.0 x ULN) without any other apparent cause. A diagnosis of Gilbert's syndrome will be based on the exclusion of other diseases on the basis of the following criteria: i. Unconjugated hyperbilirubinemia noted on several occasions ii. No evidence of hemolysis (normal hemoglobin, normal haptoglobin levels, reticulocyte count), and lactate dehydrogenase iii. Normal liver function tests iv. Absence of other diseases associated with unconjugated hyperbilirubinemia\n   * Aspartate aminotransferase (AST) \\[serum glutamic-oxaloacetic transaminase (SGOT)\\] and alanine aminotransferase (ALT) \\[serum glutamate pyruvate transaminase (SGPT)\\] =\\\u003C 3 x ULN\n   * Albumin \\>= 2.5 mg\u002FdL\n   * International normalized ratio (INR) or prothrombin time (PT) =\\\u003C 1.5 x ULN unless subject is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants\n   * Activated partial thromboplastin rime (aPTT) =\\\u003C 1.5 x ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants\n7. Female subject of childbearing potential should have a negative urine or serum pregnancy within 7 days prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n8. Female subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 5 months after the last dose of study medication.\n9. Male subjects must agree to use an adequate method of contraception and refrain from donating sperm, starting with the first dose of study therapy through 5 months after the last dose of study therapy\n\n   * Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.\n\nExclusion Criteria:\n\n1. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment\n2. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. Participants who have received acute and\u002For low-dose systemic immunosuppressive medications (e.g., a one-time dose of dexamethasone for nausea or chronic use of \\\u003C=10 mg\u002Fday of prednisone or dose-equivalent corticosteroid) may be enrolled in the study after discussion with and approval by the Sponsor. The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) is allowed\n3. Has a known history of active Bacillus tuberculosis (TB).\n4. Has an acute primary infection or reactivation of Epstein-Barr virus (EBV).\n5. Known allergy or hypersensitivity to any of the study drugs or their excipients.\n6. Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =\\\u003C grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier\n7. Has had prior targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =\\\u003C grade 1 or at baseline) from adverse events due to a previously administered agent or radiation therapy\n8. Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy, in situ cervical cancer, low-grade thyroid cancer and prostate cancer that is in remission under androgen deprivation-therapy for \\> 2 years or under watchful waiting with Prostate-specific antigen (PSA) doubling time \\> 6 months. Additional malignancies may be permitted after consultation with the Principal Investigator. Other exceptions may apply and require discussion between the Investigator and the Sponsor\n9. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment\n10. Has known history of, or any evidence of active, non-infectious pneumonitis requiring corticosteroids\n11. Patient has known history of stage 2 or higher chronic obstructive pulmonary disease (COPD). Stage 2 COPD is defined as forced expiratory volume in one second (FEV1)\u002Fforced vital capacity (FVC) \\\u003C 70%; 50% \\\u003C FEV1 \\\u003C 80% predicted, with dyspnea on exertion\n12. Patient has asthma requiring systemic corticosteroids at the time of screening. Inhaled corticosteroids for the treatment of asthma are permitted\n13. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator\n14. Has known medical, psychiatric or substance abuse disorders\u002Fconditions that in the opinion of the principal investigator would interfere with cooperation or interfere with safe completion of the trial.\n15. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment\n16. Has received prior therapy with an anti-CTLA4, anti-PD-1, anti-PD-L1, or anti-PD-L2 agent\n17. Has known active hepatitis B \\[e.g., hepatitis B surface antigen (HBsAg)\\] reactive) or hepatitis C \\[e.g., hepatitis C virus (HCV) ribonucleic acid (RNA) quantitative has been detected\\]. HBsAg reactive on appropriate antiviral therapy with suppressed hepatitis B virus (HBV) deoxyribonucleic acid (DNA) less than 100 IU\u002FmL and eligible liver function will be allowed\n18. Current New York Heart Association (NYHA) class III or higher heart failure. Patients with a prior history of heart failure that has resolved to class II or lower may participate\n19. Patient has been treated with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or is anticipated to need such a vaccine during the course of the study or within 5 months after the last dose of atezolizumab. Note for Arm C (atezolizumab + tocilizumab): Because IL-6 inhibition may interfere with the normal immune response to new antigen, patients should be brought up to date on all recommended vaccinations, except for live vaccines, prior to initiation of therapy with tocilizumab to maximize vaccine response.\n20. Known human immunodeficiency virus positive (HIV+) patients may be included but must have:\n\n    1. A stable regimen of highly active anti-retroviral therapy (HAART)\n    2. No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\n    3. A cluster of differentiation 4 (CD4) count above 250 cells\u002FmcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based tests\n21. Major surgery (including joint surgery, excluding needle biopsies) within 8 weeks prior to screening or planned major surgery within 6 months following treatment allocation.\n22. Previous or Concomitant Medications\n\n    1. Previous treatment with any cell-depleting therapies, including investigational agents or approved therapies, some examples include: CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-Cluster of Differentiation 19 (CD19) and anti-CD20.\n    2. Treatment with intravenous gamma globulin, plasmapheresis or Prosorba column within 6 months of baseline.\n    3. Previous treatment with tocilizumab (an exception to this criterion may be granted for upon application to the sponsor on a case-by-case basis).\n    4. Any previous treatment with alkylating agents such as chlorambucil, or with total lymphoid irradiation.\n    5. History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies.\n23. Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary (including obstructive pulmonary disease), renal, hepatic, endocrine (include uncontrolled diabetes mellitus) or gastrointestinal disease (including complicated diverticulitis, ulcerative colitis, or Crohn's disease.)\n24. Any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to screening.\n\n    a. Participants who receive prophylactic antibiotics for biopsy are eligible for the study.\n25. Patients with reproductive potential not willing to use an effective method of contraception.\n26. Patients with lack of peripheral venous access.\n\n    Additional Exclusion Criteria for Arm B (Atezolizumab + Tiragolumab)\n27. Patients with a history of anaphylactic reactions to human, chimeric, or mouse monoclonal antibodies or to any components of tiragolumab.\n\n    Additional Exclusion Criteria for Arm C (Atezolizumab + Tocilizumab)\n28. Known active infection of bacterial, viral, fungal, mycobacterial or other infections, including, but not limited to, TB (i.e., has signs and symptoms of TB) and atypical mycobacterial disease, hepatitis B and C, and herpes zoster, but excluding fungal infections of nail beds.\n29. Pre-existing central nervous system (CNS) demyelinating or seizure disorders.\n30. History of diverticulitis, chronic ulcerative lower gastrointestinal (GI) disease (e.g., crohn disease, ulcerative colitis), or other symptomatic lower GI conditions that might predispose a patient to GI perforation.\n31. Current liver disease unrelated to the underlying cancer diagnosis, as determined by the investigator.\n32. History of, or currently active, primary or secondary immunodeficiency.",{"count":766,"type":22},55,[25],"To determine the effect of neoadjuvant atezolizumab alone or in combination with other immune modulating agents on T-cell infiltration in advanced SCCHN. To determine the impact of neo-adjuvant immunotherapy on surgical outcomes.",[329,31,770,653],"Squamous Cell Carcinoma",[329,772,773],"Non-Virally Associated Squamous Cell Carcinoma","Head and Neck","2025-01-24",{"date":776,"type":40},"2025-01-28",{"date":778,"type":40},"2019-03-08",{"date":780,"type":22},"2028-06-30",{"name":782,"class":164},"Alain Algazi"]